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ABSTRACT

Chemokines are structurally and functionally related 8-10 kDa proteins
defined by four conserved cysteine residues. They consist of a superfamily of
proinflammatory mediators that promote the recruitment of various kinds of
leukocytes and other cell types through binding to their respective chemokine
receptor, a member of the GPCR family. Abnormal control of this system results
in various diseases including tumorigenesis and cancer metastasis. Deregulation
can occur when constitutively active mutant (CAM) chemokine receptors are
locked in the “on” position. This can lead to cellular transformation/tumorigenesis.
A viral CAM receptor, ORF74, that can cause tumors in humans, also has
homology to human CXC chemokine receptor 2 (CXCR2), which is a G-proteincoupled receptor (GPCR) expressed on neutrophils, some monocytes,
endothelial cells, and some epithelial cells. CXCR2 activation with ELR+ CXC
chemokines induces leukocyte migration, trafficking, cellular differentiation,
angiogenesis and cellular transformation. Using a high throughput yeast screen
we identified a novel point mutation, D9H, in CXCR2, which leads to constitutive
activation (CA). Generation of positively charged substitutions, D9K and D9R,
and D143V as a positive control resulted in CA CXCR2 with differential levels of
cellular transformation. To further investigate how D9 mutations lead to
differential CA, we used inhibitors of known signal transduction pathways.
Pertusiss toxin (PTX) sensitivity in foci formation assays demonstrated that D9R
uses the Gi subunit like WTCXCR2 and D143V, while D9H and D9K do not. All
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CA receptors use the JAK pathway based on sensitivity to the inhibitor, AG490.
Phosphorylation of PLC-beta 3 and sensitivity to the PLC-beta 3 inhibitor,
U73122, implicates that mutant receptors such as D143V, D9H, D9K, and D9R
utilize the Gq/11 subunit. Interestingly, D9R use both Gi and Gq/11 subunits. All of
the CA receptors induced phosphorylation of the epidermal growth factor
receptor (EGFR) indicating a transactivation between CXCR2 and EGFR. These
data describe two novel and important findings. First, N-terminal CXCR2 controls
activation and signaling using multiple G protein subunits to elicit downstream
signaling. Second, our work supports the “functional selectivity” model for GPCR
activation. That is, mimicking agonist activation, CA CXCR2 receptors have
multiple conformational states that lead to differential activation.
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PART I. GENERAL INTRODUCTION

CHAPTER 1. G PROTEIN-COUPLED RECEPTORS

An Overview
Since the structure of the G-protein coupled receptor (GPCR), rhodopsin
was crystallized and solved [1] [2], technological advances have expanded the
structure and function of GPCR superfamilies. Also, the number of identified
GPCRs has grown rapidly and now consists of nearly 1,500 unique full-length
members [3-5]. GPCRs are one of the largest and most diverse groups of
proteins in the human genome [4, 6]. These proteins can bind to a broad range
of exogenous stimuli including light, odor, and taste [6, 7], as well as endogenous
ligands including peptides and hormones (e.g. angiotensin, bradykinin,
endothelin, and melanocortin), biogenic amines (e.g. adrenaline, dopamine,
histamine, and serotonin), nucleosides and nucleotides (e.g. adenosine,
adenosine triphosphate, and uridine triphosphate), peptide pheromones (e.g.
alpha-factor and a-factor in a variety of fungi), and lipids and eicosanoids (e.g.
cannabinoids, leukotrienes, prostaglandins, and thromboxanes) [8] (Table 1 and
Figure 1).
GPCRs play an important role as a physical conduit of extracellular
signals across the cellular membrane inducing complex biological processes and
function through intracellular heterotrimeric G proteins [9-11]. G proteins are
comprised of non-identical α (~33-35 kDa), β (~35 kDa), and γ (~15 kDa)
subunits [5].

	
  

2	
  

Class: A Rhodopsin-like receptors
Family I

Olfactory receptors, adenosine receptors,
melanocortin receptors, and others

Family II

Biogenic amine receptors

Family III

Vertebrate opsins and neuropeptide receptors

Family IV

Invertebrate opsins

Family V

Chemokine, chemotactic, somatostatin, opioids and others

Family VI

Melatonin receptors and others

Class B: Calcitonin and related receptors
Family I

Calcitonin and calcitonin-like receptors

Family II

PTH/PTHrP receptors

Family III

Glucagon, secretin receptors and others

Family IV

Latrotoxin receptors and others

Class C: Metabotropic glutamate and related receptors
Family I

Metabotropic glutamate receptors

Family II

Calcium receptors

Family II

GABAb receptors

Family IV

Putative pheromone receptors

Class D: STE2 pheromone receptors
Class E: STE3 pheromone receptors
Class F: cAMP and archaebacterial opsin receptors

Table 1. Sequence-based groupings within the G-protein-coupled receptors

Abbreviation: PTH, Parathyroid hormone receptor; PTHrP, Parathyroid hormone
related peptide receptor; GABAb, γ-Aminobutyric acid receptor
Modified from Flower et al [12].
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Figure 1. Classification and diversity of GPCRs.
Class A GPCRs are characterized by several highly conserved amino acids in
the TMs and there is usually a disulfide bridge linking extracellular loops 1 and 2.
Most of the class A receptors have a palmitoylated cysteine residue in the
intracellular C-terminal tail. The binding sites of the endogenous small-molecule
hormone ligands of class A GPCRs are located within the 7 TM bundle (A-1, the
ligand binding site is indicated in orange). For peptide and glycoprotein hormone
receptors (A-2 and A-3, respectively), binding occurs at the N terminus, the
extracellular loop segments and the extracellular domains of the TM helices.
Class B GPCRs contain a relatively long N-terminal tail (B). The class B
receptors show a number of conserved proline residues within the TMs. The
majority of class C receptors are characterized by very large N- and C-terminal
tails, a disulfide bridge connecting the first and second extracellular loops,
together with a very short and well-conserved third intracellular loop (C). A
number of the highly conserved residues of class A GPCRs are also strongly
conserved in class C GPCRs. The ligand binding site is located in the N-terminal
domain, which is composed of the so-called venus flytrap (VFT, gray color filled
region) module that shares sequence similarity with bacterial periplasmic amino
acid binding proteins. In all class C GPCRs except the GABAb receptor, a
cysteine-rich domain (CRD), which contains nine conserved cysteine residues,
links the VFT to the 7 TM domain.
Modified from Jacoby et al [13].
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Mammalian G proteins are comprised of one of 17 α-subunits combined with one
of 5 β-subunits and one of 12 γ-subunits, which provides an extraordinary
combinatorial potential for inducing signal transduction pathways [5, 14] (Table
2).
The common structural features of GPCRs are seven transmembrane
(TM)-spanning α-helical domains, an extracellular N-terminus, an intracellular Cterminus, and three loops on each side of the membrane [9]. Interaction of the
GPCRs with their ligands causes a conformational alteration, which induces the
dissociation of the G protein α-subunit from the GPCR and the βγ-subunit leading
to the exchange of GDP with GTP [15, 16]. Activation of the G proteins transmits
a signal through effectors, such as adenylyl cyclase and phospholipase Cβ [5]
(Table 3).
Because of the high degree of selectivity and sensitivity between GPCRs
and their ligands, they function as key modulators for complex biological
processes such as neurotransmission, hormone and enzyme release from
endocrine and exocrine glands, immune responses, cardiac- and smooth-muscle
contraction and blood pressure regulation.

Malfunction of GPCR mediated

processes can lead to a variety of disorders including cancer development and
progression [17-19]. Considering the broad range of GPCR-modulated biological
processes, GPCRs are attractive drug targets for pharmaceutical companies. In
fact, they are the top target proteins for pharmaceutical discovery programs [20].
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Table 2. The class and subunits of heterotrimeric G proteins, gene names
and localization in mammalian cells.

to be continued on the next page
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Table 2-continued. The class and subunits of heterotrimeric G proteins,
gene names and localization in mammalian cells.

Modified from Malbon [5]
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Table 3. Heterotrimeric G-protein subunits and their functions.

Abbreviation: GRK, G-protein receptor kinase. Modified from Malbon [5].
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Currently GPCRs are the molecular targets of about 30% of all marketed drugs,
50% of all modern prescription drugs, and 25% of the top-selling drugs [13, 21,
22]. Moreover only approximately 30% of all known GPCRs, mainly in the
biogenic amine family (a subfamily of class 1 GPCRs), have been targeted with
drugs. However, many novel GPCRs have been reported as ‘orphan’ receptors
because their function and endogenous ligands are still unknown [21, 23, 24].
Research on GPCRs could potentially contribute to our understanding and
eventually contribute to the development of treatments for diseases involving
GPCRs.

GPCR ACTIVATION
GPCR activation is induced by a variety of ligands [4, 8]. The focus of
GPCR research is the identification of the binding domains for ligands using
genetic, biochemical, and biophysical techniques. For understanding the
structure-function relationship between GPCRs and their ligands, molecular
techniques such as site-directed or random mutagenesis, domain swapping, and
the use of labeled probes have been used to identify the important residues and
domains [25].

The binding sites of endogenous “small-molecule” ligands in

family 1 receptors, such as for the retinal chromophore in rhodopsin and
catecholamines in the adrenergic receptors have well characterized receptorbinding domains [26-28]. Recent studies on the binding domains of peptide
receptors such as the receptors for angiotensin [29-31], parathyroid hormone [32,
33], secretin [34], bradykinin B2 [35, 36], gonadotropin-releasing hormone [37],
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opioids [38, 39], neurokinin (NK) [40, 41], vasopressin/oxytosin [42-44],
cholecystokin/gastrin [45, 46], and neurotensin 1 [47] have been extended into
other classes of GPCRs. Although there are some common features among
ligands, there are a variety of unique interactions between GPCRs and their
cognate ligands. For instance, large ligands, including proteins, bind to
extracellular loops, whereas small molecules ligands, such as pharmacological
agents, bind within the TM region of GPCRs (Figure 1). Peptides ligands present
a combination of the two processes. The peptides primarily bind to the
extracellular loops and part of the ligand may penetrate into the transmembrane
region at the same time and interact with residues buried within the lipid bilayer
[48-51].
Before the crystal structure of ligand-activated human β2 adrenergic
receptor (β2AR) was solved [52], simplistic models were generated where
GPCRs were simple binary switches that could be in either an inactive and active
forms. However, GPCRs are no longer considered simple ON/OFF switches.
Instead they are more like rheostats that are dynamic and assume many different
conformations [53, 54].

Recently, multi-state models suggest that GPCRs

spontaneously shift between multiple active and inactive conformations in order
to explain their complex GPCR activation states [55, 56]. The 5-HT2-serotonin
receptors [57] α2A-adrenoceptors [58], AT1 receptor [59], gonadotropin-releasing
hormone receptors [60], µ-opioid receptors [61] and many others have different
receptor conformations supporting the multi-state model. Based on the multistate model, the concept of ‘functional selectivity,’ ‘agonist-directed trafficking’, or
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‘biased agonism’ have been used to describe how different ligands for a specific
receptor can induce different conformations of the receptor [62]. Recently, the
these different terms have been narrowed to either ‘functional selectivity’ or
‘ligand-induced differential signaling’ to describe this phenomenon [63].
In addition to functional selectivity, ‘ligand efficacy’ addresses the complex
functional behavior of GPCRs. Ligand efficacy is used to describe the effect of a
ligand on the structure and biophysical properties of a receptor [55]. Natural and
synthetic ligands can be divided into four different efficacy classes: ‘full agonists’
are able to maximally activate the receptor; ‘partial agonists’ induce submaximal
activation even at saturating concentrations; ‘neutral antagonists’ show no effect
on signaling activity but can prevent other ligands from binding to the receptor;
‘inverse agonist’ decrease basal or constitutive activity [55].

GPCR Signaling
Initially, G proteins were described as guanine-nucleotide regulatory
proteins that functionally link the receptor with effectors. The initial description of
G proteins was glucagon stimulation of adenylyl cyclase through the secondary
effector cyclic AMP in rat liver cells [64]. The G protein, Gs, was purified and
shown to be a heterotrimeric structure, composed of a α, β, and γ subunit [65,
66]. Each of these subunits are comprised of 17 α subunits, 5 β subunits, and 12
γ subunits [5]. The α subunit is GDP-bound and forms a complex with one β
subunit and one γ subunit, which functionally dissociate from the βγ complex
when it binds GTP. Mostly the α subunit is the active form when it is bound to
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GTP and regulates the activity of downstream effectors [15]. Commonly, G
proteins are designated by their α subunit, which means the Gs heterotrimeric
complex includes Gαs; Gq includes Gαq; Gi includes Gαi; and so on. The four
major α subunit subfamilies are Gαs, Gαi, Gαq, and Gα12. Gαs is activated by a
large group of GPCRs and stimulates adenylyl cyclase, which induces the
synthesis of cyclic AMP from ATP. In contrast to Gs, Gαi inhibits adenylyl cyclase
actitivity. Gαq activates phospholipase Cβ and Gα12 activates Rho-GuanineNucleotide Exchange Factors (GEFs) [5, 67] (Figure 2). Pertussis toxin (PTX)
was the first tool for characterizing G-protein-dependent signaling processes.
PTX specifically inactivates all members of the Gαi family of G proteins (Gαi1,
Gαi2, Gαi3, GαoA, GαoB, Gαt1, Gαt2 and Gαz). All other G proteins are insensitive to
PTX [67]. PTX catalyses the ADP-ribosylation of a conserved arginine residue
(Arg-178 in Gαi1, Arg-201 in Gαs and Arg-174 in Gαt) on Gα proteins resulting in
inhibition of both GTPase activity and its interaction with Gβγ (Table 3) [68-70].
In addition to Gα subunits, the Gβγ dimer itself also has an ability to
induce signal transduction pathways modulating its own set of effectors, such as
phospholipase Cβ, adenylyl cyclase, and K+ channels [71-76] (Table 3).
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Figure 2. Classical overview of GPCR signal transduction pathways.
Normally GDP are bounded in Gα subunit under the inactive state lacking ligand
binding. Ligand binding to the GPCR induces GPCR activation, which causes
GDP exchange with GTP and dissociation between Gα and βγ subunit. In the
case of the β2 adrenergic receptor, agonist binding leads to receptor activation
that induces Gαs activation. This activation stimulates secondary effector,
adenylyl cyclase, which induces accumulation of cyclic AMP. The accumulated
cyclic AMP activates a serine/threonine kinase, protein kinase A (PKA)
activation. PKA activation leads to phosphorylation of various kinases and
transcriptional factors. The βγ subunit modulates α subunit independent
pathways.
Adapted from Pierce et al [67].
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The β and γ subunits form a functional unit that only can be dissociated under
denaturing conditions. Even though most β subunits can interact with most γ
subunits, not all possible combination of subunits have been identified [4, 77]. β
and γ proteins are found in a wide variety of cell types except 1 Gβ and 5 Gγ
proteins, which are expressed in selective tissues, such as the brain or taste
buds (Table 2). Therefore, overlapping signaling cascades through Gβγ can also
increase the complexity of intracellular signaling. To terminate the signal,
hydrolysis of GTP to GDP is controlled by the regulator of G protein signaling
(RGS) protein leading to reassociation of the heterotrimer and the termination of
the activation cycle. The extraordinary combinational complexity of αβγ
heterotrimers limits the ability to identify signal transduction pathways induced by
G proteins, in spite of technological advances [67].
In addition to the classical G protein signaling pathways an additional layer
of complexity has been added to models of GPCR activation. For example, β2AR
shows coupling to both Gαs and Gαi in cardiac myocytes [78] but can also induce
a signal transduction cascade through MAP kinase pathways, which is mediated
in a G protein-independent manner through β-arrestins [79, 80]. Because of the
complexity of theses pathways, specific G protein subunit pairs that function on
specific signal transduction pathways have rarely been shown.
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Constitutively Active Mutant GPCRs
Ligand-independent GPCR activation that leads to G-protein activation is
called constitutive activity [81]. Since the first constitutively active mutants (CAMs)
were identified in α1-adrenergic receptor in 1990 [82], CAMs have been identified
in almost all classes of GPCRs and are not limited to specific secondary
messengers. Because unstimulated wild type GPCRs have differential basal
activity from fully inactive to completely active, the exact definition of a CAM
remains controversial [83]. The general definition of a CAM is is a receptor that
has an increase in basal activity compared to its wild type counterpart without
stimulation [81, 83].
GPCR activation requires an alteration of the wild type conformation in
order to trigger G protein activation. This activation also induces the activation of
other protein involved in signal transduction and receptor trafficking.

These

include protein kinase A (PKA) and protein kinase C (PKC), or a family of Gprotein-coupled receptor kinases (GRKs). Generally GPCR activity is downregulated with GRK and β-arrestins. In fact, GRK phosphorylation induces
binding of arrestin proteins to the receptor and inhibits further interactions
between the receptor and the G protein [84-86]. CAM GPCRs mimic, to some
degree, the active conformation of the wild type receptor and spontaneously
adopt a structure that is able to activate G proteins [81]. Therefore, the position
and characteristics of the CAMs potentially provides a snapshot of the structural
differences between the inactive and the active states of GPCRs.
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Kjelsberge et al [87] suggested the loss of intramolecular interactions
induces a gain-of function CAM phenotype implying the existence of structural
constraints that maintain the silence of a ligand-free receptor. They described a
mutation of Ala293 to any other of the 19 amino acids in the α1B-adrenergic
receptor resulted in constitutive activation [87]. Interestingly, a number of GPCRs
in family A have been characterized by the conserved motif, D/ERY, at the
junction of third TM domain and intracellular loop as the main structural
constraint for maintaining the receptor inactivation. Mutation of the first residue of
this motif in rhodopsin [88], α1B-adrenergic receptor [89], β2-adrenergic receptor
[90], gonadotropin-releasing hormone receptor [91] M1 muscarinic receptor [92],
CXC chemokine receptor 2 (CXCR2) [93] or the lutropin/choriogonadotropin
receptor [94] leads to constitutive activation. Two models possibly explain the
constitutive activity in these mutants. One model suggests that the mutation
might disrupt the constraining interactions of the arginine residues in TM1, 2, and
7 [87, 89, 95]. However another model that is broadly accepted has constitutive
activity mediated through the disruption of an ionic interaction between the
arginine and the aspartic or glutamic acid of the motif [2, 91, 96]. Alternatively,
the D/ERY motif might regulate the active state the CAMs using other
mechanisms.
Other domains have been shown to be important for GPCR activation as
well. One example is the large ectodomain of the luteinizing hormone receptor
[97] or thyroid stimulating hormone receptor [81]. This region constrains the TM
region maintaining the inactive state and its deletion leads to constitutive
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activation. In addition the long C-terminal intracellular domain (more than 350
residues) of the metabotropic glutamate receptor 1 constrains G protein
activation.

A number of splice variants of the C-terminal domain induce

constitutive activity [98]. Interestingly, no CAMs of GPCRs encoding a mutation
on N-terminus have been reported except CAM of thyloid stimulating hormone
receptor (TSHR) that present a mutation in large N-terminal exodomain [99, 100].

Constitutively Active Mutant Viral GPCRs
Given the flexibility of GPCR signaling and its promiscuous contribution to
different physiological processes, it seems obvious that viruses would have
evolved proteins to exploit these receptors for their evolutionary advantage.
These pirated receptors could function to aid in recognition and infection of
permissive cells or for activating host signaling in order to evade immune
recognition or aid in replication [101].
Many DNA-viruses, such as Kaposi sarcoma-associated herpesvirus
(KSHV), Epstein–Barr virus (EBV), human cytomegalovirus (HCMV), and human
herpesvirus 6 and 7 encode GPCRs that have been hijacked from their cellular
hosts and rendered constitutively active following mutations in key structural
motifs. Several CAM GPCRs have recently been implicated in virally-induced
oncogenesis [102]. One example is KSHV, the causative agent of Kaposi’s
sarcoma (KS) [103] and primary effusion lymphoma [104]. The KSHV genome
encodes a GPCR, ORF74, whose closest homologues are the chemokine
receptors CXCR1 and CXCR2 [105]. KSHV ORF74 binds a variety of
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chemokines, such as CXCL-1, 2, 3, 5, 7, 8, 10 and 12 [106]. Chemokines, such
as CXCL-1 and CXCL-8, can further activate ORF74 or function as neutral
ligands [107].

Others, such as CXCL-10 and CXCL-12, can inhibit ORF74

signaling functioning as inverse agonists [108]. In addition, KSHV ORF74
induces cellular transformation in NIH3T3 cells and tumorigenesis in nude mice
[109].

Furthermore,

transgenic

mice

expressing

KSHV-ORF74

develop

angioproliferative lesions in multiple organs, which is morphologically identical
with KS [110]. These tumors are highly vascularized, contain a spindle cell
component, express VEGF-C mRNA, and many of the cells are CD31+ cells.
CD31 and VEGF-C expression are typically displayed in KS [111].
KSHV ORF74 signals through Gq based on the accumulation of inositol
phosphate from the activation of phospholipase C. In addition KSHV ORF74 is
not inhibited by PTX treatment whereas chemokine receptors couple to Gi [112].
KSHV ORF74 stimulates PI3K–AKT/Protein Kinase B (PKB) pathway in
endothelial cells, which protects them from apoptosis [113]. Therefore, the
survival of KSHV-infected endothelial cells would allow for longer survival and
production of the virus. Stimulation of AKT/PKB in KSHV-ORF74-expressing
cells is dependent on βγ subunits of the G protein in both PTX-sensitive and insensitive G proteins [93, 105]. In addition to G-protein mediated signaling, Gprotein independent signal transduction was reported. Burger et al showed that
KSHV-ORF74 constitutively induces the activation of the JAK-STAT3 pathway
[114] (Figure 3).
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Figure 3. KSHV-ORF74 induced signal transduction pathways mediated by
both Gαi and Gαq.
G-proteins, Gαi and Gαq, drive PI3K (red arrow) and PLC-β (blue arrow)
dependent intracellular cascades, respectively. In addition Gβγ also induces
PI3K mediated signaling. G-protein independent kinase (orange dotted arrow),
and JAK-STAT3 (orange arrow), are also induced by ORF74. KSHV ORF74
ligand-independently activates various transcriptional factors. Abbreviations: PLC
(Phospholipase C), PKC (Protein kinase C), MEK (Mitogen activated protein
kinase

kinase),

MAPK

(Mitogen

activated

protein

kinase),

PI3K

(Phosphatidylinositol 3-kinases), PKB (Protein kinase B), JAK (Janus activated
kinase), STAT3 (Signal transducers and activators of transcription protein), AP1(Activator protein-1), CREB (cyclic-AMP-response-element-binding-protein),
NFAT (Nuclear factor activator of T cells), HIF-1α (Hypoxia-inducible factor-1α).
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GPCRs in Cancer
Experimental and clinical evidence indicates that GPCRs have a critical
role in cancer progression and metastasis. However these mechanisms cannot
completely explain all origins of cancer. Recently it has been suggested that
malignant cells hijack the normal physiological function of GPCRs leading to
autonomous proliferation, immune evasion, increased nutrient and oxygen
supplies, invasion of the surrounding tissues, and dissemination to other organs
[19].

Cancer cells will often overexpress GPCRs and their subsequent

stimulation via autocrine or paracrine agonists released by tumor or stromal cells
stimulate GPCRs and their signal transduction pathways. In fact, many GPCRs
are overexpressed in different cancers (Table 4) and contribute to tumor cell
proliferation mediated through autocrine and paracrine activation. For instance,
the activation of chemokine receptors such as CXCR2 after stimulation with
interleukin-8 (IL-8, also known as CXCL8) and GRO-α (also known as CXCL1
and melanoma growth stimulatory activity α) from tumor cells contributes
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Table 4. GPCRs in cancers.
GPCRs and their cognate ligand interaction contribute to tumor growth, survival,
metastasis, invasion and/or angiogenesis.
Abbrevivation: AT (angiotensin receptor), β1AR and β2AR (β1- and β2adrenergic receptors), CCK (cholecystokinin), ETA (endothelin receptor type A),
ETB (endothelin receptor type B), GPR30 (G protein- coupled receptor 30),
GRPR

(gastrin-releasing

peptide

receptor),

IL8

(interleukin

8)

LPA

(lysophosphatidic acid), MC1R (melanocortin 1 receptor), MSH (melanocortin 1),
NMBR (neuromedin B receptor), PAR-1(ptotease-activated receptor-1), PGE2
(prostaglandin E2), SDF1 (stromal cellderived factor 1).
Modified from Dorsam and Gutkind [19].
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to the progression of some tumors, such as squamous carcinomas of the head
and neck (HNSCC) and melanoma [115, 116]. GPCRs are also considered key
mediators of inflammation, thus providing a possible connection between chronic
inflammation and cancer. Inflammation is considered an important component in
tumorigenesis and offers novel therapeutic targets [117-119]. Furthermore
GPCRs, especially chemokine receptors, play a central role in tumor-induced
angiogenesis and could induce GPCR-guided migration of cancer cells to other
organs. Cancer cells manipulate GPCR signaling to attract endothelial cells and
lead them to invade the tumor mass, thereby forming new vessels to provide
nutrients and oxygen. Therefore, distracting or inhibiting GPCRs and their
downstream targets might provide an opportunity for the development of novel
mechanism-based strategies for cancer diagnosis, prevention, and treatment [19].
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CHAPTER 2. CHEMOKINES AND CHEMOKINE RECEPTORS

An Overview
Initially chemokines were defined in 1989 as novel cytokines activating
neutrophils [120]. They consist of a superfamily of proinflammatory mediators
that promote the recruitment of leukocytes, and other cell types through GPCRs
[121-123]. Chemokines contain a heparin-binding domain in the C-terminus that
is responsible for binding to proteoglycans in the extracellular matrix [124].
Chemokines have been classified into 4 subfamilies, based on the spacing of the
cysteines in the amino terminus: CXC, CC, CX3C and C [125]. Among
chemokine subfamilies, CXC chemokines are further classified into Glu-Leu-Arg
(ELR)+ and ELR− CXC chemokines, based on the presence or absence of the
ELR motif in the N-terminus. IL-8, epithelial neutrophil activating protein (ENA
also known as CXCL5), granulocyte chemotactic peptide-2 (GCP-2 also known
as CXCL6), neutrophilic activating protein (NAP also known as CXCL7),
melanoma growth stimulatory activities (MGSA (or GRO) α, β and γ also known
as CXCL1, CXCL2 and CXCL3) belong to the ELR+ CXC subfamily [125].
The ELR motif in the N-terminus of CXC chemokines modulates their
specificity for binding to their cognate receptors. For example, ELR+ CXC
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Figure 4. Chemokine superfamily and their cognate chemokine receptors.
Chemokines are classified based on the location of the highly conserved cysteine
residues (orange round) in the N-terminus. There are four families, such as C,
CC, CXC and CX3C chemokines. “x (blue round)” represents any amino acid
between cysteine residues. Each chemokine interacts with their chemokine
receptors expressed on a variety of cell types including leukocytes, epithelial and
endothelial.
Adapted from Sodhi et al [102].
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chemokines in the N-terminus of the molecule that immediately precedes the first
cysteine are potent promoters of angiogenesis [126, 127]. By contrast, ELRCXC chemokines, such as platelet factor-4 (PF-4) and interferon gammainducible protein-10 (IP-10), are potent inhibitors of angiogenesis [128]. The
structural dissimilarity in the N-terminus of these CXC chemokines plays an
important role in receptor specificity. Based on the unique functional differences
of the CXC chemokines, there has been increasing interest in their ability to
regulate angiogenesis in cancer [124].
The function of the chemokine is initiated upon binding to their chemokine
receptors, a member of the GPCR family [122]. Initially two specific chemokine
receptors for IL-8, CXCR1 and CXCR2, were identified on the cell surface [129,
130]. Since then, 18 functional chemokine receptors have been identified [131].
In addition there are two ‘decoy’ or ‘scavenger’ receptors, DARC and D6, which
are known to bind several chemokines but do not induce signaling. It has been
speculated that their function may be to modulate inflammatory responses
through their ability to remove chemokine ligands from inflammatory sites [131].
There are a number of common characteristics of chemokine receptors.
All chemokine receptors identified so far are membrane-bound proteins
composed of an N-terminus, 7-transmembrane domains, 3-extracellular and
intracellular loops and a C-terminus, and can couple to G-proteins. The
chemokine receptor is comprised of approximately 350 amino acids. The Nterminus of the receptor is relatively shorter than other GPCRs and contains
many acidic residues and N-linked glycosylation sites. An intracellular C-terminus
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contains serine and threonine residues that act as phosphorylation sites for
receptor regulation. Also, a disulfide bond links highly conserved cysteines in
extracellular loops 1 and 2 [132].
Chemokine receptor 4, CXCR4, has drawn a lot of attention recently
because it is a co-receptor for human immunodeficiency virus (HIV) [133] and its
involvement in tumor progression and metastasis [134, 135]. CXCR4 was
originally cloned as an orphan chemokine receptor, which is expressed on
neutrophils, myeloid cells, and T lymphocytes [136]. Two years later CXCR4 was
identified as a cofactor for T-tropic HIV-1 and HIV-2 envelope-mediated fusion
and entry into CD4+ T cells [133]. The ELR- CXC chemokine, stromal cellderived factor (SDF-1α (also known as CXCL12)) is the only host ligand for
CXCR4 and is a highly effective lymphocyte chemoattractant. It interferes with
HIV-1 infection of permissive CD4+ cells in accordance with CXCR4 expression
patterns [137, 138]. Stimulation with IL-4 induces an increase in cell-surface
expression of CXCR4 on resting peripheral and cord blood T cells, whereas
stimulation with CD28 or CD3 and CD2 lead to down-regulation of CXCR4
expression [139]. CXCR4 knockout mice exhibit impaired B lymphopoiesis,
myelopoiesis, hematopoiesis, derailed cerebellar neuron migration, and defective
vascularization of the gastrointestinal tract [140-142] illustrating its role in a
variety of developmental processes. CXCR4 is abnormally expressed on a
variety of tumor cells, such as breast, head and neck, small-cell lung cancer
(SCLC) and non-small-cell lung cancer (NSCLC). CXCR4 stimulation is believed
to play an important role in tumor cell proliferation, survival, angiogenesis and
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migration [19]. Interestingly metastatic tumor cells express higher levels of
CXCR4 than primary tumors in SCLC, NSCLC, neuroblastoma, melanoma,
HNSCC, colorectal, thyroid, prostate, ovarian and renal-cell cancers, as well as
in

multiple

haematopoietic

malignancies,

including

chronic

lymphocytic

leukaemia, multiple myeloma and acute leukaemia. This circumstantial evidence
implicates a central role for CXCR4 and SDF-1α in tumor progression and
metastasis [19, 143, 144].

CXCR4 is the best example of the role that

chemokine receptors play in tumor development and progression.

CXCR2 Activation and Signaling
Most chemokines stimulate more than one chemokine receptor and many
chemokine receptors are functionally activated by a number of chemokines [125].
IL-8 activates CXCR1 and CXCR2. Both receptors are highly homologous (77%)
[129, 130], with most of the divergence in the N-terminus (29%) and ECL2 (55%)
regions [145]. CXCR1 selectively bind either IL-8 or GCP-2, whereas CXCR2 can
interact with CXCL-1, 2, 3, 5, 6, 7 and 8 [123]. Activation of both receptors upon
ligand binding induces phosphatidylinositol (PI) hydrolysis, intracellular Ca2+
mobilization, and chemotaxis. All can be inhibited with PTX, indicating that the
both receptors couple to Gαi in neutrophils where Gαi2 is very abundant [120,
146]. A major difference between CXCR1 and CXCR2 is phospholipase D
activation, which is mediated via CXCR1 activation, implicating that the two
receptors have different cellular functions [147]. In addition to phospholipase D
activation, receptor trafficking is a distinguishing characteristic between CXCR1
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and CXCR2, which induces leukocyte activation and regulation in response to IL8 [148, 149]. Over 95% CXCR2 internalizes within 5 min of activation with IL-8
compared with about 10% for CXCR1 [150, 151]. This implies that receptors are
regulated differently upon stimulation and that they induce differential signaling.
Initially CXCR2 was cloned in 1991 from human promyelocytic leukemia
cells, HL60s [129]. CXCR2 is expressed on various cell types and tissues
including neutrophils, monocytes, eosinophils, mast cells, basophils, lymphocytes,
epithelial cells, endothelial cells, smooth muscle and cells of the central nervous
system [152]. Treatment of CXCR2 expressing cell lines with PTX completely
disrupted

IL-8

mediated

inhibition

of

forskolin-stimulated

cyclic

AMP

accumulation indicating that CXCR2 activation induces Gαi dependent signal
transduction pathways [153]. This Gαi dependent signaling stimulates the
accumulation of intracellular inositol phosphate and increases intracellular
calcium. CXCR2 activation, followed by the initiation of G proteins including βγ
subunit mediated signals, induces important downstream regulators of
intracellular signaling such as cAMP/protein kinase A (PKA), protein kinase C
(PKC),

phospholipase

C

(PLC),

phosphoinositide

3-kinase

(PI3Kinase)/AKT/mTOR, Ras/Raf/MEK/JNK/p38/ERK1/ERK2, and activates NFkB pathways. These pathways subsequently induce proliferation, migration, and
inhibition of apoptosis [154-157].
Initially, Burger et al [93] demonstrated a constitutively activate mutant
CXCR2 could be generated with a single point mutation in the highly conserved
DRY motif (D138V). This residue was chosen based on KSHV ORF74. KSHV
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ORF74 is constitutively active and induces tumorigenesis.

This receptor

encodes a VRY motif instead of a DRY motif at the junction of the TM3 and ICL2.
The CXCR2 mutant (D138V) induced cellular transformation in NIH3T3 cells that
is comparable to KSHV ORF74. To evaluate G protein-coupled signaling through
the PLC pathway, accumulation of inositol phosphate in NIH3T3 cells expressing
D138V mutant was measured.

KSHV ORF74 and the CXCR2 (D138V) mutant

increased the amount of inositol phosphate 3.5 and 3.0 fold higher than
untransfected NIH3T3 cells.. PTX treatment did not completely inhibit the
accumulation of inositol phosphate for both the KSHV ORF74 and the D138V
mutant, which suggests that the D138V mutant induces an agonist-independent
signal transduction pathway similar to the KSHV ORF74. In addition, both
receptors showed only a small Ca2+ response upon IL-8 stimulation suggesting
constitutive activity is independent of ligands. Constitutively active mutant
CXCR2 (D138V) mediated cellular transformation was dependent on constitutive
STAT3 phosphorylaton on Tyr705 as part of JAK2 activation [114]. This laid the
foundation for our current studies of CAM CXCR2 and their role in cellular
transformation.

CXCR2 IN TUMORIGENESIS
The

role

of

CXCR2

mediated,

ELR+

CXC

chemokine-induced

angiogenesis in vivo has been investigated using the corneal micropocket assay
for angiogenesis. Interestingly CXCR2-/- mice or CXCR2+/+ mice treated with
neutralizing antibodies (Abs) to CXCR2 interfered with ELR+ CXC chemokine-
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mediated angiogenesis [158]. This evidence demonstrated that CXCR2 is both
essential and sufficient to mediate the angiogenic effects of ELR+ CXC
chemokines. Because of its role in angiogensis and the role that angiogensis
plays in tumor formation, there has been an increasing focus on CXCR2 and its
relationship to cancer. Another in vivo model described a correlation between the
expression of endogenous ELR+ CXC chemokines that induce tumor growth and
the metastatic potential of Lewis lung cancer (LLC) tumors in CXCR2+/+ mice.
The LLC primary tumors and spontaneous metastasis to the lungs were
significantly reduced in CXCR2-/- mice. Morphometric analysis of the primary
tumors in CXCR2-/- mice described areas with greater tumor-associated necrosis
and reduced tumor-associated angiogenesis when compared with tumors grown
in CXCR2+/+ mice. These findings were further confirmed in CXCR2+/+ mice
treated with neutralizing Abs to CXCR2 [159]. This evidence supports the view
that CXCR2 mediates the angiogenic activity of ELR+ CXC chemokines in a
preclinical model of lung cancer.
IL-8, activation of CXCR1 and CXCR2 induces mitogenic and angiogenic
factors that contribute to human cancer progression [160]. Higher-grade human
melanoma specimens and metastases express higher levels of CXCR2
suggesting an association between the expression of IL-8 and CXCR2 [161].
Singh et al [162] demonstrated that CXCR1 or CXCR2 overexpressed in nontumorigenic and low-tumorigenic melanoma cells enhanced cellular proliferation,
chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2
overexpression in non-tumorigenic melanoma cells induces tumorigenicity as
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examined in vivo [162].

In addition IL-8-induced and CXCR1- or CXCR2-

dependent melanoma cell proliferation and migration was mediated through the
ERK1/2 MAP kinase pathway. However, the functional significance of these
receptors, CXCR1 and CXCR2, in melanoma progression remains unclear [162].
In human ovarian cancer cells, SK-OV-3, CXCR1 and CXCR2 are strongly
expressed. IL-8 stimulation through p44/42 MAP (Erk1/2) kinase transformed
ovarian

cancer

cells

to

have

increased

membrane

ruffling

and

the

formation/retraction of thin actin-like projections. All of these phenotypes are
indicators cancer cell metastasis [163].
Overexpression of CXCL-1 and 2 (also known as GRO-α and β) and
CXCR2 in esophageal squamous cell carcinoma tissues, WHCO1, 5 and 6,
demonstrated an important role for CXCR2 activation in cellular proliferation. This
proliferative autocrine loop between GRO α/β and CXCR2 indicated a critical role
for CXCR2 in the development and maintenance of squamous esophageal
cancer [164].
Heterotropic and orthotopic models of murine renal cell carcinoma using
CXCR2-/- and CXCR2+/+ BALB/c mice demonstrated that CXCR2 induces tumorassociated angiogenesis and tumor growth. In this murine model, CXCR2 ligand
(CXCL-1, 3, 5 and 8) expression directly correlated with tumor growth in
CXCR2+/+ mice. In contrast, a significant reduction in tumor growth in CXCR2-/mice was observed and correlated with decreased angiogenesis and increased
tumor necrosis [165].
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Human prostate cancer biopsy tissue analysis showed a progressive
increase in IL-8 expression in the early stages (Gleason 3 or 4) compared with
normal prostate epithelium [166]. Elevated IL-8 expression was also detected in
the serum of prostate cancer patients. There was a 2-5 fold higher elevation of
IL-8 in patients with prostate cancer compared with normal or benign prostatic
hypertrophy patients [167]. In addition, the localization of IL-8 and CXCR1 and 2
expression to the cytoplasm and the basal membrane of prostate cancer cells
was even more distinct in the transurethral resection of the prostate biopsy
samples of advanced and androgen-independent disease (Gleason pattern 5)
[166]. The androgen-independent prostate cancer cell line, PC3, exhibited high
IL-8 expression and activation of its receptors, CXCR1 and CXCR2, which
promoted tumorigenicity of the cells [166].
The human pancreatic cancer cell line, Capan-1, had increased IL-8 and
CXCL-1 expression, and these chemokines induced mitogenic effects through
CXCR1 and CXCR2 in vitro [168]. Additionally CXCR2 inhibition completely
abolished neovascularization in the human pancreatic cancer cell line, BxPC-3
[169].
The highly metastatic colon cancer cell line, KM12L4, expressed higher
levels of IL-8 and cognate receptors, CXCR1 and CXCR2, than the low
metastatic cell line, KM12C, and non-metastatic cell line, Caco2. Also IL-8
stimulation induced higher cellular proliferation for Caco2 than KM12C and
KM12L4 cell lines respectively. Inhibition of IL-8, CXCR1, or CXCR2 reduced
cellular proliferation in both KM12C and KM12L4 cells. Moreover, the expression
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level of IL-8 was directly involved in the migratory potential of colon cancer cell
[170]. These data suggest that IL-8 and its receptors potentially modulate human
colon cancer tumorigenesis.
Taken together, CXCR2 activation induced by its ligands is a contributing
factor to tumor-associated angiogenesis, tumorigenesis and metastasis.
Development of novel agents targeting multiple angiogenic mediators is currently
in progress [171, 172]. Among those targets, CXCR2 is one of the best
candidates for anti-angiogenic therapies in that it is the universal receptor for all
angiogenic CXC chemokines. Therefore targeting CXCR2 along with other
angiogenic factors is a promising strategy to overcome tumorigenesis and
metastases in a variety of cancers [159, 165].

Summary and Statement of Research Aims
The metastatic potential of primary tumors correlates with tumor
proliferation and the level of tumor-related angiogenesis [165, 173]. In fact, solid
tumors lacking a vascular conduit cannot grow more than several cubic
millimeters, because nutrients and gas exchange cannot occur [165, 173].
Evidence suggests that the function of CXCR2 in tumor formation, proliferation
and metastasis is associated with its expression and activation in endothelial
cells. CXCR2-induced neovascularization promotes tumor cell proliferation
providing tumor cell access to the vasculature [159, 165]. Based on this
information, CXCR2 is an attractive target for inhibiting tumor-related
angiogenesis. CXCR2 binds to all angiogenic ELR+ CXC chemokines and the
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inhibition of CXCR2 results in the lack of angiogenic activity in vivo. Many studies
show that CXCR2 inhibition promotes a significant decrease in tumor size and an
increase in tumor necrosis in vitro and in vivo [159, 165].

The main focus of this dissertation is not only the role of constitutive
activation of CXCR2 followed in cellular transformation, but also the mapping of
intracellular signal transduction pathways mediated by constitutive activation.
The hypothesis of this dissertation is that the CAM CXCR2 induced by an Nterminal single point mutation promotes tumor development. To investigate this
hypothesis, the following research objectives were performed:
1. Screening and identification of CXCR2 CAMs using the yeast model
system
2. Verification of tumorigenicity mediated by CXCR2 CAMs in vitro and in
vivo.
3. Identification of an intracellular signal transduction cascades induced by
CXCR2 CAMs.
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PART II. SCREENING FOR NOVEL CONSTITUTIVELY
ACTIVE CXCR2 MUTANTS AND THEIR CELLULAR
EFFECTS
In Press as “Screening for Novel Constitutively Active CXCR2 Mutants and
their Cellular Effects” Methods in Enzymology: Constitutive Activity and
Inverse Agonism, Giljun Park, Tom Masi, Chang K. Choi, Heejung Kim, Jeffrey
M. Becker, and Tim E. Sparer
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CHAPTER 1. ABSTRACT
Chemokines play an important role in inflammatory, developmental, and
homeostatic processes. Deregulation of this system results in various diseases
including tumorigenesis and cancer metastasis. Deregulation can occur when
constitutively active mutant (CAM) chemokine receptors, which are locked in the
“on” position. This can lead to cellular transformation/tumorigenesis.
The CXC chemokine receptor 2 (CXCR2) that has homology with CAM
receptor, ORF74 is a G-protein-coupled receptor (GPCR) expressed on
neutrophils, some monocytes, endothelial cells, and some epithelial cells.
CXCR2 activation with ELR+ CXC chemokines induces leukocyte migration,
trafficking, leukocyte degranulation, cell differentiation, and chemokine mediated
angiogenesis. Activation of CXCR2 can lead to cellular transformation. We
hypothesized that CAM CXCR2s may play a role in cancer development. In order
to identify CXCR2 CAMs, mutant CXCR2s were screened using a modified
Saccharomyces cerevisiae high-throughput system. Saccharomyces cerevisiae
has been successfully used to identify GPCR and G-proteins interactions and
autocrine selection for peptide agonists. The CXCR2 CAMs identified from this
screen were characterized in the mammalian system. Their ability to transform
cells in vitro was shown using foci formation, soft-agar growth, impedence
measurement assays and in vivo tumor growth following hind flank inoculation.
Signaling pathways contributing to cellular transformation were identified using
luciferase reporter assays. Studying constitutively active GPCRs is an approach
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for “capturing” a pluridimensional GPCRs in a “locked” activation state. In order
to

address

the

residues

necessary

for

CXCR2

activation,

we

used

Saccharomyces cerevisiae for screening novel CAMs and characterized them in
mammalian reporter assays.
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CHAPTER 2. INTRODUCTION
Although

there

are

many

contributing

factors

to

tumorigenesis,

chemokines and their receptors can contribute to tumorigenesis and metastasis
[134]. Chemokines function normally as small chemoattractant cytokines that are
involved in inflammatory, developmental, and homeostatic processes [174].
Deregulation of this system is associated with the development of cancers and
metastasis. One example of disruption of the chemokine pathway is the
constitutively active mutant (CAM) receptors [134, 175]. These CAMs cause an
alteration of the structural constraints, locking it into an active conformation. This
conformational change induces ligand independent activation called constitutive
activity [176]. CAM GPCRs are associated with the development of a variety of
human diseases [177]. The best example of a constitutively active chemokine
receptor causing cancers is the Kaposi sarcoma herpesvirus chemokine
receptor, ORF74, which is a homolog for human CXCR2 [108]. This receptor
has a ‘VRY’ motif instead of a ‘DRY’ motif between third transmembrane domain
and second intracellular loop and has been shown to be constitutively active.
Stable lines of NIH3T3 fibroblasts expressing ORF74 lead to cellular
transformation [93, 106, 178]. These transfectants are tumorigenic in nude
mouse and a transgenic mouse expressing ORF74 developed tumors resembling
Kaposi’s sarcoma (KS) lesions [111].
CXC chemokine receptor 2 (CXCR2) is a G-protein-coupled receptor
(GPCR) [179] and expressed on neutrophils, some monocytes, endothelial cells,
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and some epithelial cells [180]. Activation of CXCR2 with ELR+ CXC chemokines
leads

to

leukocyte

migration,

trafficking,

leukocyte

degranulation,

cell

differentiation, and ELR+ CXC chemokine mediated angiogenesis [123] [181].
Utilizing the induction of the natural pheromone response pathway,
Saccharomyces cerevisiae has been successfully used to identify GPCR/Gproteins interactions and selection of peptide agonists [182-185]. Recently
allosteric peptide agonists for CXCR4 were identified using this system. The
pheromone responsive pathway was modified to include a hybrid G-protein to
interact with CXCR4, elimination of growth arrest genes, and an auxotrophic
marker under the control of the pheromone responsive element. With these
modifications a library of CXCR4 ligands was screened to identify novel agonists
[186].
To identify CXCR2 CAMs, the open reading frame (ORF) of CXCR2 was
randomly mutated and expressed in this genetically engineered yeast. Using a
simple selection for growth on media lacking histidine we identified novel CXCR2
CAMs.

Constitutive

activation

was

confirmed

with

induction

of

beta-

galactosidase, which was under the control of the pheromone responsive
element. In order to characterize the CXCR2 CAMs in the mammalian system
and to link them to cellular transformation, the first step in tumorigenesis, we
generated stable transfectants using CXCR2 CAMs and measured foci
formation, anchorage-independent growth in soft agar, impedance, and tumor
formation in vivo. To address the downstream constitutively active signal
transduction pathways immunoblotting and flowcytometry were used to identify
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specific phosporylated signaling pathways. Luciferase reporter constructs with
CREB, STAT3, and NF-kB responsive elements can be used to identify important
signaling pathways that could contribute to cellular transformation. Here we
describe

detailed

approaches

for

successful

characterization of CXCR2 CAMs.
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identification

and

cellular

CHAPTER 3. MATERIALS AND MATHODS

Strains, media, and plasmids
Yeast strain CY1141 (MATα FUS1p-HIS3 can1 far1*1442 gpa1 (41)G@ai2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3) contains an
integrated copy of a hybrid Gα subunit (GPA1(41)Gαi2) in which the N-terminal 33
residues of human Gαi2 are substituted with the 41 N-terminal residues of GPA1
[185]. For strain CY12946 (MAT2 FUS1p-HIS3 GPA1G@ai2(5) can1 far1*1442
his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3) also contains
a chimeric G protein GPA1Gαi2(5) in which the 5 residues of C-terminal GPA1
were replaced with the C-terminal 5 residues of human Gαi2 [187]. In addition S.
cerevisiae strain, BJS21 (MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52
ste2::KanR) was used as a control to see the receptor expression on the plasma
membrane.
Yeast expression vector, p426GPD (ATCC, #87361), was used to clone
wild type and mutated human CXCR2. To estimated basal activity of receptor
pMD1325 (a gift from Dr. Dumont, University of Rochester, School of Medicine
and Dentistry) were transformed into yeast.
YPD is a basic enriched media to culture BJS21, CY1141 and CY12946,
which contains 1% of BactoYeast extract (Difco), 2% of BactoPeptone (Difco),
and 2% dextrose. For selective medium MLU (medium lacking uracil) contains 1x
Yeast Nitrogen Base (YNB) without amino acids plus ammonium sulfate (Difco),
2% glucose, 1% casamino acids (Difco). When also selecting for histidine and/or
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leucine in combination with uracil the casamino acids is not added due to it
containing both histidine and leucine.

Cell lines, growth medium, mouse strain and plasmids
NIH3T3 (ATCC) and HEK293 (ATCC) were maintained in the medium
containing DMEM with 10% bovine calf serum (Hyclone). 6 to 8 week old athymic
nu/nu mice (Jackson Laboratory) were used for in vivo tumogigenesis assay.
pcDNA3.1 (Invitrgen) and pcDNA3.1+GFP plasmids were used to clone wild type
and mutants CXCR2 into mammalian cell line. Lipofectamine 2000TM (Invitrogen)
was used for transfection. Neomycin (G418 Sulfate, Cellgro) was applied to
select single clonal population.

Reagents for Yeast transformation
1.0 M lithium acetate (LiAc) and 50% (w/v) polyethylene glycol (PEG)
3350 are sterilized with 0.2 and 0.45 µm pore size filtration respectively and
stored at room temperature. Single strand DNA (ssDNA, salmon sperm DNA,
Sigma-Aldrich) is boiled for 10 min, cooled down on ice, and frozen at -20
degrees Celsius.

Reagents for Yeast Immunofluorescence
Potassium phosphate (KPi, 0.1 M, pH 6.5), SHA (1 M Sorbitol, 0.1 M
NaHepes (pH 7.5), 5 mM NaN3), 4% formaldehyde, β-mercaptoethanol, and
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yeast cell wall lytic enzyme (Fisher, Cat.No. BP2683-25). WT buffer: 1% fat free
dry milk, 0.5 mg/ml BSA, 150 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Tween
20, and 1 mM NaN3. For anti-CXCR2 immunoblotting an antibody specific for
human CXCR2 (sc-7304, SantaCruz Biotechnology) is used. HRP-conjugated
secondary

Ab

was

applied,

and

then

detected

with

enhanced

chemiluminescence system (ECL, Amersham). Hoechst dye (1 µg/ml, Molecular
Probe) for nuclear staining is used to identify individual cells.

Reagents for Subcellular fractionation
Sorbitol buffer (10 mM Tris (pH 7.6), 0.8 M sorbitol, 10 mM NaN3, 10 mM
KF, 1 mM EDTA, pH 8.0), and sucrose buffer (10 mM Tris (pH 7.6), 1 mM EDTA,
10% [w/v] sucrose) were used.

Reagents for Immunoblotting
NuPAGE 12% Bis-Tris SDS-polyacrylamide gel (Invitrogen) and PVDF
membrane (Invitrogen) were used. Primary antibodies: anti-FLAG M2 antibody
(Eastman

Kodak

Co.)

and

anti-human

CXCR2

(sc-7304-SantaCruz

Biotechnology), and secondary antibody: anti-mouse HRP-conjugated secondary
Ab (eBioscience) were applied. Blocking media (1% dried milk in PBS/0.1%
Tween 20) and wash media (PBS/0.1% Tween 20) were prepared.

ECL

development kit (Amersham) and 2x SDS Sample Buffer (Invitrogen) were
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applied. PE-conjugated human CXCR2 specific antibody (R&D Systems,
FAB331P) for FACs anaysis was applied.

Reagents for error-prone PCR
Primers forward and reverse for the CXCR2 ORF were synthesized to
include

unique

restriction

sites

(Forward

with

HindIII

5’-

CCCAAGCTTATGGAAGATTTTAACATGGAGAGTG-3’ and Reverse with XbaI
5’-GCTCTAGATTAGAGAGTAGTGGAAGTGTGC-3’). Low fidelity Taq polyerase
(Fisher BioReagents) is preferred for error-prone PCR than high fidelity Taq
polymerase. In addition dATP, dGTP, dTTP, dCTP, and manganese chloride
were added separately to the reaction because they were modified in order to
increase the error rate of the PCR reaction.

Reagents for β-galactosidase assay
Basal activity of β-galactosidase was measured using a yeast βgalactosidase assay kit (Pierce) according to the manufacturer's instruction. The
amount of β-galactosidase is expressed as Miller units.

Yeast transformation
Maintain and culture yeast strains on YPD medium. Inoculate a fresh
colony into 5 ml YPD and incubate with movement overnight at 30°C. Using the
overnight culture inoculate 50 mls of YPD in a sterile flask to a final density of
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5x106 cells/ml. Incubate the culture as above until a cell concentration of 2x107
(usually 3-5 hours) is achieved. Centrifuge the cells at 4,000 rpm for 5 minutes
and discard the supernatant. Wash the cells one time in 25 ml sterile water,
centrifuge and then resuspend in 1 ml of 100 mM LiAc and transfer to a 1.5 ml
microcentrifuge tube. Centrifuged the cells at top speed in a microcentrifuge for
15 seconds and remove the LiAc. Resuspend the cells in 400 µl of 100 mM LiAc.
For each plasmid to be transformed, aliquot 50ul of cells to a clean microfuge
tube. Boil the ssDNA for 5 min, and keep on ice until needed. Centrifuge each
aliquot of cells and the discard the supernatant. In the following order, carefully
add each of the following reagents: 240 µl of 50% PEG, 36 µl of 1.0 M LiAc, 25 µl
of ssDNA, 5 µl (0.1-10 µg) of cloned DNA (e.g. wild type CXCR2 cloned into
p426 GPD) and 45 µl of sterile water. Vortex the mixture until cell pellet is
completely resuspended (about 1-2 min). Include a negative control reaction
without cloned DNA. Incubate the mixture at 30°C for 30 min and heat shock at
42°C for 25 min. Centrfuge the heat shocked cells at top speed in a
microcentrifuge for 2 min, and then remove the supernatant. Resuspend the cells
in 1 ml of sterile water and plate 200 µl on selective media lacking uracil and
incubate at 30°C. Transformed yeast colonies will be seen in 2-3 days.

Yeast Immunofluorescence analysis
Fix 1×108 cultured yeast cells in 0.1 M KPi (pH 6.5) and 4% formaldehyde
for at least 1 hr then centrifuge and resuspend again in fix (as above) for at least
12 hrs but less than 24 hrs. After fixation, resuspend the cells in 5 ml of SHA (1
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M Sorbitol, 0.1 M NaHepes, pH 7.5, 5 mM NaN3) and store at 4°C for up to 2
weeks. To remove the cell wall, incubate 500 µl of the resuspended cells in 1 ml
of SHA, 0.2% of β-mercaptoethanol, and 10 mg/ml of yeast cell wall lytic enzyme
(Fisher, BP2683-25) at 30°C for 1.5 hrs. After incubation, centrifuge the cells and
resuspended in 1% SDS, wash with 1ml of SHA and resuspend with SHA (~100
µl). After spinning down the cells, incubate the cells with a primary specific
human CXCR2 antibody (sc-7304, SantaCruze Biotechnology) (1:100 dilution in
WT buffer (1% fat free dry milk, 0.5 mg/ml of BSA, 150 mM of NaCl, 50 mM
HEPES (pH 7.5), 0.1% Tween 20, and 1 mM NaN3)) overnight at 4ºC. Wash the
cells 5 times with WT buffer, and then add a FITC labeled anti-mouse secondary
antibody (sc-2099, SantaCruz Biotechnology) (1:1,000 dilution in WT buffer).
After incubation at room temperature for 30 min, wash the cells 5 times with WT
buffer and stain with 100 µl of Hoechst dye (1 µg/ml, Molecular Probes). Wash
the cells 3 times in sterile water and store at 4ºC in the dark. Take
photomicrographs using an Olympus BX 50 microscope and photograph with
Pictureframe version 2.3 (Olympus).

Subcellular fractionation
Harvest 1×107 cells grown in selective medium lacking uracil, wash once
with 1 ml sorbitol buffer (10 mM Tris, pH7.6, 0.8 M sorbitol, 10 mM NaN3, 10 mM
KF, 1 mM EDTA, pH 8.0), centrifuge and remove supernatant. Wash again with 1
ml sucrose buffer (10 mM Tris pH7.6, 1 mM EDTA, 10% [wt/vol] sucrose), and
then resuspend the cells in 1 ml sucrose buffer containing protease inhibitors (10
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µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, and 2 µg/ml pepstatin A).
Mechanically disrupt the cells with glass beads and centrifuge at 300xg for 5 min
to remove any unlysed cells. Mix 0.5 ml of supernatant with 0.5 ml of 50 %
(wt/vol) sucrose in 10 mM Tris (pH 7.6), 1 mM EDTA, and layer on top of a 4 ml
of 30-60% linear sucrose gradient prepared in 10 mM Tris (pH 7.6) and 1 mM
EDTA. For the gradient separation, overlay the cells on the sucrose cushion and
centrifuge at 150,000×g for 20 hours. Collect fractions (≈250 µl) from bottom of
the gradient by inserting a long blunt-end needle into the bottom of the tube.
Make sure that the needle rests on the bottom of the ultracentrifuge tube. Dilute
10 µl of each fraction 1:1 in 2x sample buffer. Warm samples for 10 min at 37ºC
and then load on a NuPAGE 12 % Bis-Tris SDS-polyacrylamide gel (Invitrogen).
Other gels can be substituted but this manufactured gel gave the best-looking gel
for publication. Transfer the proteins via wet transfer onto a PVDF membrane
(Invitrogen).

After transfer, block the membrane in 1% non-fat dried milk in

PBS/0.1% Tween 20. The yeast pheromone receptor, Ste2p-FLAG, which is
expressed by the BJS21 strain, was used as a positive control for plasma
membrane expression of the receptor. After blocking, probe the membrane for
Ste2p-FLAG expression with an anti-FLAG M2 antibody (1:25,000 dilution,
Eastman Kodak Co.) and human CXCR2 antibody (1:10,000 dilution, sc-7304,
SantaCruz Biotechnology) together, which were incubated at 4ºC overnight.
Make all dilutions in wash buffer. Wash twice with PBS/0.1% Tween 20, then
add
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secondary

Ab

(1:10,000

dilution,

eBioscience) for 30min.

Wash blots 4x with PBS/0.1% Tween 20 and then

detect with ECL (Amersham).

Identification of CXCR2 CAMs in the yeast strains
CXCR2 CAMs were identified in the FUS1-HIS3 yeast strains when they
grew on medium lacking uracil, histidine and in the presence of 3-amino-1,2,4triazole (3-AT), which is used to suppress endogenous HIS expression. The
CAMs activate the chimeric G proteins resulting in activation of the pheromone
response pathway and subsequent activation of the fus1 promoter upregulating
the HIS auxotrophy gene. In order to confirm and quantify the degree of
constitutive activation, a plasmid containing β-galactosidase (lacZ) under the
control of the FUS1 promoter was transformed into these strains. The plasmid
FUS1-lacZ (pMD1325) allows expression of lacZ after induction of the
pheromone pathway. This plasmid also contains a LEU2 selectable marker for
selecting transformants [188]. Once the transformants were created, the amount
of β-galactosidase produced was quantified using a standard kit.

Random mutagenesis
Perform random mutagenesis by using error-prone PCR [189]. Synthesize
primers up and downstream of the CXCR2 ORF to include unique restriction
sites for cloning into the expression vector (HindIII and XbaI).

Alter three

parameters in order to increase the mutagenic potential of the PCR reaction.
First, use low fidelity Taq polymerase (Fisher BioReagents). Second, adjust the
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final concentration of dTTP/dCTP to 0.8 mM while keeping the remaining
nucleotides at 0.25 mM [190]. Alteration of the ratio of nucleotides increases the
likelihood of misincorportions during the amplicon synthesis.

Finally, add

manganese chloride to a final concentration of 500nM. Manganese chloride
concentrations lower than 500 nM are less mutagenic. Digest the PCR products
from random mutagenesis with HindIII and XbaI, and ligate into the p426GPD
yeast expression vector by standard cloning procedures. Select yeast colonies
(about 200) on media lacking uracil. Extract plasmid encoding the CXCR2 CAMs
by using a yeast plasmid miniprep kit (ZymoprepTM, ZYMO RESEARCH). Then
transform the extracted yeast plasmid E.coli (MAX Efficiency® DH5α™ Competent
Cells, Invitrogen) in order to acquire enough DNA for sequencing. Purify the
CXCR2 CAMs/p426GPD plasmid using a miniprep kit (Promega) and sequence
using primers flanking the multiple cloning regions.

β-galactosidase assay
Plasmid pMD1325 (gifted from Dr. Dumont) contains a FUS1-lacZ that is
inducible by receptor activation [188]. β-galactosidase assay was performed as
previously described [191]. Briefly, grow transformed yeast strains CY1141
and/or CY12946 (with the p426GPD expressing CXCR2 CAMs and pMD1325)
overnight in selective growth media at 30ºC until they reach 5×106 cells/ml. Wash
with sterile water, and grow at 30ºC in selective media for one doubling based on
a hemocytometer count, Measure basal activity of β-galactosidase using a yeast
β-galactosidase assay kit (Pierce) according to the manufacturer's instructions.
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This allowed the comparison of β-galactosidase production from yeast
expressing the wild-type CXCR2 containing strains normalized to the activity of
each mutant.

Transfection of NIH3T3 cells to establish stable cell lines
expressing CXCR2 CAMs
In a 6-well dish transfect 2 µg of DNA and 4 µl of lipofectamine 2000
(Invitrogen) into 5x106 NIH3T3 cells. The transfection efficiency was optimized by
varying DNA and lipofectamine concentrations with an indicator plasmid such as
pcDNA3.1 expressing GFP. About 24-48 post transfection, change the growth
medium with medium supplemented with 0.8 g/L of G418 sulfate. Replace the
medium with fresh selection media and wash with ice-cold PBS every 3 days for
14-21 days. This is the period required for the selection of stably transfected
NIH3T3 cells. Untransfected NIH3T3 cells will detach and will be washed away
during the medium exchanges. Once all of the cells have died in the
untransfected control, keep the growing cells in selective medium until colonies
develop. Once colonies have formed, remove media from the plate and circle
colonies with a colored pen on the bottom of the plate. Choose 5-10 colonies per
construct to check for expression. Place a cloning disc (Scienceware) that has
been soaked in trypsin-EDTA solution (Hyclone), over the top of the colony for 23 minutes. Place the disc containing the stable clone into a well of a 24-well plate
containing selection media. Change the media everyday until the cells have
achieved 80-90% confluency. Trypsinize the confluent well of cells and transfer
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to a 6-well dish and maintain in selection media until 80-90 % confluency.
Expand the cells into a T-25 cell culture flask and analyze for CXCR2 expression.
Verify the surface expression of the receptor for each of the clonal population by
immunostaining followed by flow cytometery analysis using a FACs machine
(Calibur, BD biosciences). Trypsinize 1×106 stably transfected cells, wash with
ice-cold PBS and then block with 1% goat serum in PBS. Incubate cells with a
PE-conjugated human CXCR2 specific antibody (R&D Systems, FAB331P) for
30 min at room temperature.

Wash cells once with PBS and fix with 4%

paraformaldehyde and analyze by flowcytometry.

After verifying expression,

expand cells and store in 10% DMSO in media in the freezer (-140 ºC) (liquid
nitrogen is adequate) until further analysis. This is step is important as NIH3T3
cells will spontaneously transform upon passages above 10-15.

Characterization of CXCR2 CAMs in mammalian cells
To characterize the constitutive activity of the different CXCR2 CAMs,
NIH3T3 stable cell lines were assessed for anchorage independent growth and
the loss of contact inhibition [192]. Additionally, impedance measurements
allowed quantitative measurements of cellular proliferation and morphological
changes associated with cellular transformation. This electrochemical technique
has been applied to biological studies that include cellular barrier function,
attachment, spreading, and adhesion [193] [194] [195] [196]. To characterize the
specific genes that may be involved these morphological changes, luciferase
reporter assay were utilized. For example, Cannon and Cesarman [197]
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demonstrated that KSHV ORF74 constitutively activates transcription of AP-1,
NF-kB, CREB, and NFAT-responsive promoters using luciferase assays. The
ultimate test of whether these CXCR2 CAMs lead to tumorgenicity, was the
implantation of cells into the hind flank of nude mice and measuring tumor
formation in vivo.

Foci formation assay
Seed 100 stably transfected NIH3T3 cells on top of 2×105 untransfected
NIH3T3 cells in normal growth medium with a CXCR2 antagonist, SB225002
(Calbiochem) added to a final concentration of 1µM. This is added in order to
prevent growth of the WT CXCR2 transfectants, which may respond to CXC
chemokines present in the serum. Change the growth media every 2 or 3 days.
After 5-7 days the cells should start to form colonies. 10-14 days after initial the
seeding, fix the cells in 70% ethanol and stain with crystal violet solution. If the
cells grow too fast and begin to detach from the plate, stop the culture earlier and
fix and stain. To enumerate the number of colonies, photograph the well and
analyze the images using ImageJ version 1.43 (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/,
1997-2009).

Soft-agar growth assay
Blend a total of 1×103 stably transfected NIH3T3 cells in pre-warmed
(37°C) 0.4 % soft-agar containing regular medium, and then pour the mixture on
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top of 0.8 % agar in a 6-well plate. Feed cells every 3 days with 5 drops of media
per well. After incubation for 3 weeks, add 500 µl of 0.5 mg/ml piodonitrotetrazolium violet and incubate for overnight at 37°C. Photograph wells
and visualize colonies under an image analyzer (LAS 4000, Fujifilm Co.). Count
and measure the number and size of colonies using ImageJ.

Electrical impedance measurements for cellular proliferation
Figure 5 shows schematic diagrams, three key factors, and exemplified
images in regard to cellular micro-impedance measurement. Impedance is the
frequency-dependent opposition of a conductor to the flow of an alternating
electrical current. An alternating current is used for bioelectrical impedance
measurement because it penetrates the cells at low levels of voltage and
amperage. The corresponding experimental setup consists of lock-in amplifier,
data acquisition board, computer, and electrodes. Dynamic biophysical analysis
is followed by cellular micro-impedance data obtained by using LabVIEW
(National Instruments Corp.). An ac 1 Vrms reference signal via a series 1 MΩ
resistor is provided as a reference voltage. A National Instruments SCXI-1127
switch is successfully employed to connect the various working electrodes with
the counter electrode of each array. The source voltage generator resistance
(Rs) was 50 and the input impedance equivalent to a parallel resistor (Rv) and
capacitor (Cv) combination of 10 MΩ and 10pF, respectively.
During the cellular micro-impedance scans, data is acquired at a rate of 32
Hz for 2 seconds using a 30 ms filter time constant and 12 dB/decade roll off.
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Averages and standard deviation estimates are obtained from the 64 sampled
data points over the 2 second time intervals. During the experiments, cultures are
maintained at 37 °C and 5% CO2. Naked scans are always preceded to optimize
the sensitivity, to check for any electrodes debris or defects and, most
importantly to be used as reference levels for normalization. After repeated
careful examination to select pertinent a cell density, a total of 3×104
transfectants and untransfected NIH3T3 cells are inoculated in 400 µl normal
growth medium onto the electrode. One well remained untreated to provide a
control.

Electrical impedance measurements for the foci formation
assay
The impedance apparatus, as described above, is also employed to
dynamically examine colony-like foci formation of mutated cell lines. 400 µl of
normal growth medium containing 6×104 untransfected NIH3T3 cells is filled in
each well to produce a cellular base layer providing growth factors. A total of
3×104 transfectants, or untransfectant controls, are seeded on top of the
untransfected NIH3T3 layer. Seeding is performed at the saturated growth time
point (approximately 27 hours) with another 100 µl normal growth medium.
Impedance measurements continue without any interruption during the seeding
process for another 61 hours to produce a second set of scans. Time-dependent
changes in the normalized resistance and reactacne can be obtained in real time.
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Figure 5. Overview of cellular micro-impedance measurement.
Impedance measurements reflect the electrical resistance and reactance across
a cellular membrane and through a cell monolayer. (A) Schematic drawings show
current flows before and after cell inoculation.

Each chamber contains a

substrate with an electrode, a layer of conductive material, an insulation layer
and a small chamber containing the cellular growth medium. As cells attach,
there is a modification of the current flow. (B) This drawing shows the three
important parameters in impedance measurements, which characterize the
cellular barrier (1) the current flow under the cells (2) the current flow between
the cells and (3) the capacitively coupled current through the cellular
membranes. (c) Cellular growth images on 250-micron diameter electrodes.
These photomicrographs show cellular changes in their morphology, their
adherence to each other, and to the substrate over time.
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The bioelectrical impedance measurement can provide an invasive, sensitive,
and quick ways of dynamically examine cellular physiological changes.

Luciferase reporter assays
To measure the basal level of NF-κB, transiently co-transfect HEK293
cells (4.0×105), in a 6-well plate, with 2.0 µg of 3X MHC-Luc [198], 0.5 µg of pRLCMV as an internal control, and 0.5 µg of CXCR2 constructs with
LipofectamineTM 2000 (Invitrogen). At 24 h posttransfection, synchronize
transfected cells by serum starvation and then harvest. Assay cells with DualGloTM Luciferase Assay System following manufacturer’s instructions (Promega).

Tumor Formation in vivo
Subcutaneously inject stably expressed NIH3T3 (2×105/mice) into the
flanks of 6 to 8 week old athymic nu/nu mice (Jackson Laboratory). The protocol
for this animal experiment was reviewed and approved by the Institutional Animal
Care and Concerns Committee of the University of Tennessee. Once tumors are
beginning to appear to be seen (from 3-4 wks), measure daily. If one member in
the group achieved a tumor size of 1.5 cm, all members of the group were
euthanized. Resect, measure and place tumors into 10% buffered formalin. Cut
thin sections and stain with hematoxilin and eosin to characterize the types of
cells that have infiltrated and the morphology of the tumors themselves.
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CHAPTER 4. RESULTS

Receptor expression in the S. cerevisiae strains CY1141 and
CY12946
To

identify

the

expression

of

CXCR2

CAMs

in

the

yeast,

Immunofluorescence and subcellular fractionation were used to demonstrate
proper expression and cellular localization before beginning CXCR2 CAM
selection. Yeast strains, CY12946, expressing CXCR2 stained with an antiCXCR2 antibody (E-2, SantaCruz Biotechnology), and a nuclear was stained
with Hoechst (Molecular Probe) (Figure 6). Since the localization of the CXCR2
is not precisely distinguishable, subcellular fractionation was accomplished
(Figure 7). Yeast strain, BJS21, is known to express yeast pheromone (α-factor)
receptor, Ste2p, on the plasma membrane, which is a positive control (Figure
7A). CXCR2 stained with antibody specific CXCR2 show a same fraction with
Ste2p in BJS2i, which indicate CXCR2 localized to the plasma membrane like as
Ste2p in BJS21 (Figure 7B).
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Figure 6. Human CXCR2 expression in transformed yeast strains.
Spheroplasts were generated from CXCR2 untransformed (-) and transformed
(+) yeast strain, CY12946. Cells were fixed and stained with an anti-CXCR2
antibody (E-2, SantaCruz Biotechnology) and a nuclear stain (Hoechst,
Molecular Probe). Cells were observed and photographed using an Olympus
BX50 fluorescence microscope (100x magnification) equipped with a CCD
camera and analyzed using pictureframe version 2.3 (Olympus).
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Figure 7. CXCR2 is expressed in the CY12946 strain and localizes to the
plasma membrane.
Total membrane preparations from control strain, BJS21 that expresses Ste2p
[199], and CXCR2 transformed strain CY12946 (+) were run over a 4 ml sucrose
gradient (30-60%) and 250 ul fractions were collected from the bottom to the top
of the tube. 10 ul of each fraction was run on the SDS PAGE gel and
immunoblotted with either (A) anti-FLAG antibody or (B) CXCR2 (E-2, Santa
Cruz Biotechnology) followed by anti-mouse HRP antibody. Blots were
developed with ECL (Amersham).
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PART III. Electrical impedance measurements predict
cellular transformation
Published

as

“Electrical

impedance

measurements

predict

cellular

transformation” Giljun Park, Chang K. Choi, Anthony E. English, Tim E.
Sparer in Cell Biol. Int. 2009 Mar;33(3):429-33. Epub 2009 Jan 27.

	
  

64	
  

CHAPTER 1. ABSTRACT
Cellular transformation is the first step in cancer development. Two
features of cellular transformation are proliferation in reduced serum and
anchorage independent growth. Impedance measurements have been used to
measure proliferation and attachment in normal cells. This study describes the
use of impedance measurements to distinguish normal cells from transformed
cells. NIH3T3 cells were transformed with a constitutively active chemokine
receptor (D143V_CXCR2) and growth in reduced serum and anchorage
independent growth were measured using established biological assays and
compared to impedance measurements. The results of this study show that
impedance measurements provide a quick and reliable way of measuring cellular
transformation.

	
  

65	
  

CHAPTER 2. INTRODUCTION
In Europe, there were approximately 1.7 million deaths due to cancer in
2006 [200]. Understanding the cellular processes involved in the transformation
of a normal cell into a cancerous cell will lead to more effective cancer
treatments. There are five characteristics of transformed cells: immortalization,
growth in reduced serum, anchorage independent growth, loss of contact
inhibition, and tumor formation in nude mice. Mutations in cell cycle control genes
[201], growth factors [202], transcription factors [203] and degradation pathways
[204] can lead to cellular transformation. One of these triggers is the over
expression of a constitutively active chemokine receptor, CXCR2 [93]. The
receptor normally functions to induce cellular activation, but when it is
constitutively active, it induces cellular transformation. A single point mutation,
Aspartic acid (D)  Valine (V) at position 143, on this receptor causes the
continuous activation of signaling pathways leading to transformation [114].
Using this receptor for the transfection of mouse fibroblasts as model for cellular
transformation, the ability of impedance measurements to discern transformed
cells from normal cells was assessed.
Giaever and Keese [205, 206] pioneered the use of small micro-electrodes
with a large counter electrode to measure cellular impedances. Impedance
measurements are based on the electrical resistance and reactance across a
cellular membrane and through a cell layer. This electrochemical technique has
been applied to biological studies that include cellular barrier function,
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attachment, spreading, and adhesion [193, 195, 196, 207]. In addition, frequency
dependent electrical impedance measurements have been used to evaluate the
model parameters associated with cell-cell and cell-matrix junction formation
[208-210]. In this study, micro-impedance measurements are used to
quantitatively examine the proliferation and the morphological changes
associated with cellular transformation.
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CHAPTER 3. MATERIALS AND METHODS

Cell lines and expression vector
NIH3T3 mouse fibroblasts (ATCC, Manassas, VA), cultured in DMEM
(Dulbecco’s modified Eagle’s medium) containing 10% Fetal Calf Serum (FCS)
(Hyclone, Logan, UT), were transfected with pRc/CMV (Invitrogen) expressing
either WT_CXCR2 or D143V_CXCR2 with the Lipofectamin

TM

2000 (Invitrogen,

Carlsbad, CA) according to the manufacturer’s instructions. Stable transfectants
were selected with 800 µg/ml of G418.

Mutagenesis
To generate D143V_CXCR2, the WT_CXCR2 pRc/CMV expression
plasmid was mutagenized using the complementary primers (D143V_Forward:
5’-GCA TCA GTG TGG TTC GTT ACC TGG CCA TTG TCC ATG C-3’; D143V_
Reverse: 5’-GCC AGG TAA CGA ACC ACA CTG ATG CAG GCC AGT AGC -3’)
and a modified QuickChange® method (Stratagene). Briefly, Takara LA taqTM
polymerase (Takara Bio, Madison, WI) was used for the mutagenesis. Dpn І
treatment was followed by PCR amplification (98 °C for 3 min, 35 cycles of 98 °C
for 30 sec, 55 °C for 30 sec, and 1 cycle of 72 °C for 10 min and 72 °C for 20
min). The PCR reaction, initially cleaned with a QIAquick PCR purification kit
(QIAGEN, Valencia, CA), transformed the plasmid DNA into MAX Efficiency®
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DH5α™ Competent Cells (Invitrogen, Carlsbad, CA). Mutants, set up without
polymerase and/or without a primer, provided negative controls.

Focus formation assay
The focus formation assay was performed based on Burger et al. [93].
One hundred stably transfected NIH3T3 cells were seeded on top of 2x105
untransfected NIH3T3 cells in normal growth medium with 1 µM of CXCR2
inhibitor (SB 225002, Calbiochem, San Diego, CA). Foci were photographed and
counted after 2 weeks incubation at 37 °C and 5% CO2.

Cellular Proliferation Assay
Stable transfectants expressing either WT_CXCR2, D143V_CXCR2, or
untransfected NIH3T3 cells were plated at 1×105 cells and grown in reduced (2%)
serum at 37 °C and 5% CO2. At the time points indicated, cells were trypsinized,
stained with trypan blue (Freshney, 1987), and counted using a hemocytometer
(Bonifacino, 2001). Each time point was measured in triplicate.

Electrical impedance measurements for the cellular
proliferation assay
Figure

8

shows

a

schematic

diagram

of

the

micro-impedance

measurement apparatus. A data acquisition and analysis system was
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Figure 8. Electrical impedance measurement system schematics.
(a) A 1Vrms signal is applied to an electrode via a 1MΩ resistor, Rcc. The source
resistance, Rs, is 50Ω and the input impedance to the lock-in amplifier is
equivalent to a parallel combination of a 10MΩ resistor and 25pF capacitor, Rv
and Cv, respectively. The reference cable coaxial leads and lock-in amplifier
coaxial leads introduce parallel capacitances Cps and Cpv, into the circuit. The
electrode impedance, Zc, is estimated by voltage measurements and a voltageto-impedance conversion based on this circuit. (b) An environmental chamber
maintains a humidified, 37°C and 5% CO2 atmosphere for dynamic long timelapse measurements. The measured impedance is a function of the current flow
under the cells, between the cells, and the capacitively coupled current through
the cell membranes.
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implemented using LabVIEW (National Instruments Corp.). A reference voltage
source provided an ac 1 Vrms reference signal via a series 1 MW resistor, Rcc,
to a gold electrode array (Applied Biophysics). A National Instruments SCXI1127 switch made successive connections between the various working
electrodes and the counter electrode of each array.
generator resistance, Rs, was 50W.

The source voltage

An SR830 lock-in amplifier (Stanford

Research Instruments) with an input impedance equivalent to a parallel resistor,
Rv, and capacitor, Cv, combination of 10 MW and 10 pF, respectively, measured
the electrode voltage. Direct measurements of the cable parasitic capacitances
were made using an LCR meter and incorporated into a circuit model to estimate
the impedance based on the lock-in amplifier voltage measurements.
Preliminary naked scans were performed to optimize the sensitivity and to
check for any electrodes debris or defects. A total of 3x104 transfectants and
untransfected NIH3T3 cells were inoculated in 400 µl normal growth medium with
1 µM of CXCR2 inhibitor, SB225002, onto the electrode. One well remained
untreated to provide a control.

Electrical impedance measurements for foci formation
Using the impedance apparatus, as described above, electrodes were
inoculated with 400 µl of normal growth medium containing 6x104 untransfected
NIH3T3 cells to produce a cellular base layer providing growth factors. A total of
3x104 transfectants, or untransfectant controls, were seeded on top of the
NIH3T3 layer.
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(approximately 26 hours) using 100 µl of normal growth medium in the presences
of a CXCR2 inhibitor to give a 1 µM final concentration.

Impedance

measurements were acquired for another 61 hours to produce a second set of
scans. During the cellular micro-impedance scans, data was acquired at a rate of
32 Hz for 2 seconds using a 30 ms filter time constant and 12 dB/decade roll off.
Averages and standard deviation estimates were obtained from the 64 sampled
data points over the 2 second time intervals. During the experiments, cultures
were maintained at 37 °C and 5% CO2.
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CHAPTER 4. RESULTS

Impedance measurement for measuring cellular proliferation
One of the hallmarks of cellular transformation is growth in reduced
serum.

In order compare micro-impedance measurements with traditional

measurements of cellular growth, the growth of stable transfectants were
measured in reduced serum media. Figure 9A shows the results of harvesting
and counting the cells at different time points.

The D143V transfectant

proliferation rate is significantly greater (p<0.00001) than the WT_CXCR2 or
untransfected controls.

Figures 9B and 9C summarize the resistance and

reactance micro-impedance measurements that were carried out in parallel with
the growth measurements shown in Fig. 9A. Although resistance measurements
initially did not show a marked difference between WT_CXCR2 and
D143V_CXCR2, at 58hrs (35000 min.) the WT_CXCR2 growth plateaued while
D143V_CXCR2 continued growing for the remainder of the experiment (Figure
9B).

Micro-impedance

fluctuations,

a

measurement

of

cellular

motility/attachment, were also consistently higher in transformed cells. The
reactance measurements, however, more closely mimicked the growth curves
generated with more traditional hemacytometer measurements.

These data

show that impedance measurements can be used to distinguish growth patterns
of transformed cells compared to non-transformed cells.
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Figure 9. Impedance measurements distinguish the growth rates of
transformed verses untransformed cells.
Stable

transfectants

expressing

either

WT_CXCR2,

D143V_CXCR2,

or

untransfected NIH3T3 cells were grown in reduced (2%) serum and counted at
different time points (A). Each data point represents the mean (± s.e.m.) of three
independent experiments; (B) Normalized resistance (Rc-Rn)/Rn, recorded at 5.62
kHz, and (C) normalized reactance (Xc-Xn)/Xn, recorded at 56.2 kHz, for the
direct inoculation of untransfected and transfected NIH3T3 cells. The terms R
and X represent the resistance and reactance, respectively and the subscripts c
and n indicate cell covered and naked scans, respectively.
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Foci formation can be detected with impedance measurements
The loss of contact inhibition during cellular transformation allows these
cells to grow on top of one another forming foci. Historically, foci were counted
visually after staining with a dye such as crystal violet. Using this technique, the
number of foci formed with either WT_CXCR2 or D143V_CXCR2 transfectants
(Figure 10A, 10B) was quantified. These data show that the transformed cells
(D143V_CXCR2) form significantly more foci than WT_CXCR2 (p<0.00001).
To compare these findings with the micro-impedance measurements,
impedance measurements using an experimental set up similar to the one
described above.

The main difference is that a monolayer of untransfected

NIH3T3 cells is attached to the electrode to provide growth factors for foci
development. In spite of this more complex set up, both resistance (Figure 10C)
and reactance measurements (Figure 10D) show that D143V_CXCR2 attaches
and proliferates much more rapidly than either WT_CXCR2 or untransfected
cells. This illustrates that impedance measurements can accurately measure foci
formation as an indicator of cellular transformation.
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Figure 10. Impedance measurements assess increased attachment and foci
formation in transformed cells.
In parallel with impedance measurements, foci were measured after 2 weeks.
Stable

transfectants

expressing

either

WT_CXCR2,

D143V_CXCR2,

or

untransfected NIH3T3 cells were seeded on top of the untransfected NIH 3T3
cells, and cultured in the presence of CXCR2 inhibitor (SB 225002, Calbiochem).
(A) An example of the foci that were counted is representative of three
independent experiments.
contols.

(B) No foci were detected on the untransfected

Bars represent the mean ( ± s.e.m.) of three independent experiments

each carried out in triplicate. Impedance measurements were carried out under
a similar experimental setup. (C) Normalized resistance (Rc-Rn)/Rn, recorded at
5.62 kHz, and (D) normalized reactance (Xc-Xn)/Xn, recorded at 56.2 kHz, for
untransfected and transfected NIH3T3 cells. The terms R and X represent the
resistance and reactance, respectively, and the subscripts c and n indicate cell
covered and naked scans, respectively. For the sake of clarity, symbols
represent 30 data intervals. The arrows indicate the point of addition of either the
transfectants or untransfected controls. The increases in resistance and
reactance are consistent with increased cellular proliferation and multi-layer
focus formation.
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CHAPTER 5. DISCUSSION

Several well-known methods to examine cell proliferation include
fluorescence microscopy, flowcytometry, and biochemical assays [211]. While
these methods are stationary and need fluorescent or radioactive probes, microimpedance measurements are a bio-analytical technique capable of noninvasively and dynamically monitoring proliferation in real time without the use of
chemical probes. Another benefit is its high sensitivity to distinguish between
transformed and untransformed cells. Both the resistance and reactance of
transformed cells increased faster and to larger values than WT_CXCR2 or
untransfected NIH3T3.
The measured impedance is a sensitive and complicated function of the
degree of cellular proliferation, cell-matrix attachment, and cell-cell attachment.
As the cells proliferate and attach to the surface and each other, a systematic
increase in the measured impedance occurs.

Uncontrolled proliferation

characteristic of transformed cells is, therefore, consistent with the systematic
impedance increase observed in this study. Although, the actual impedance
values vary between different experiment runs, this pattern was consistently
observed with transformed cells compared to untransformed cells. The increase
in the microimpedance fluctuations is also consistent with increased micromotility
associated with transformed cells.
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PART IV. Novel constitutively active point mutations in
the NH2 domain of CXCR2 capture the receptor in
different activation states
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CHAPTER 1. ABSTRACT
The chemokine receptor, CXCR2, is a member of the rhodopsin family of
GPCRs. Normal CXCR2 activation leads to cellular migration, wound healing,
and angiogenesis. Using a high throughput yeast screen we identified a novel
point mutation, D9H, which leads to constitutive activation (CA). Generation of
stable transfectants expressing mutant CXCR2s (either D9H or positively
charged substitutions, D9K and D9R, or D143V as a positive control) showed
that all lead to CA but differential levels of cellular transformation (i.e. foci
formation and soft agar growth). To further investigate how D9 mutations lead to
differential CA, we used pertusiss toxin (PTX) sensitivity in foci formation assays
to show that D9R uses the Gαi like WTCXCR2 and D143V, while D9H and D9K
do not. All CA receptors use the JAK pathway based on sensitivity to the
inhibitor, AG490. Phosphorylation of PLC β3 and the sensitivity of foci formation
to the inhibitor of PLC β3, U73122, demonstrates that all utilize the Gαq subunit.
Interestingly, D9R receptors use both Gαi and Gαq. The CA receptors induce
phosphorylation of the epidermal growth factor receptor (EGFR), which suggests
transactivation between CXCR2 and EGFR. These data illustrate two novel and
important findings. First, the amino terminus of CXCR2 controls activation and
signaling via multiple G protein subunits to elicit downstream signaling. Second,
our work supports the “functional selectivity” model for GPCR activation., The
different CA CXCR2s, mimicking agonist activation, have multiple conformations
that lead to differential activation.
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CHAPTER 2. INTRODUCTION
Although

there

are

many

contributing

factors

in

tumorigenesis,

chemokines and their receptors play a role in tumorigenesis and metastasis
[134]. Chemokines function normally as small chemoattractant cytokines that are
involved in inflammatory, developmental, and homeostatic processes [174].
Deregulation of this system is associated with the development of cancers and
metastasis. One possible deregulation of chemokine activity is the constitutively
active mutant (CAM) receptor [134, 175]. CAM receptors cause the alteration of
structural constraints leading to an active conformation. This change induces
ligand independent activity called constitutive activity [176]. The CAM GPCR is a
valuable model for explaining the basic molecular events involved in the
development of a variety of human diseases [177]. The best example of
chemokine receptor constitutive activity and cancers is the Kaposi sarcoma
herpesvirus chemokine receptor, ORF74, which has a ‘VRY’ motif instead of
‘DRY’ motif between third transmembrane domain and second intracellular loop
and has been shown to be constitutively active [93, 106, 178].
CXC chemokine receptor 2 (CXCR2) is a G-protein-coupled receptor
(GPCR) [179] expressed on neutrophils, some monocytes, endothelial cells, and
some epithelial cells [152] (Figure 11). Activation of CXCR2 with ELR+ CXC
chemokines is responsible for the leukocyte migration, degranulation, cellular
differentiation, and ELR+ CXC chemokine mediated
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Figure 11. Schematic diagram of the human CXCR2 receptor.
CXCR2 consists of seven transmembrane domains (TM I – TM VII) connected by
three extracellular (EC I - EC III) and three intracellular (IC I- IC III) loops. The
conserved DRY box is shaded and the D9 residue is indicated with an arrow.
The transmembrane domains were predicted using HMMTOP, TMPred, and
PHD.
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angiogenesis [123]. Binding and activation of CXCR2 with CXCL1 (Groα) was
shown to increase melanoma growth [212]. The degree of CXCR2 expression
was shown to correlate with metastasis in a nude mouse [213]. Moreover,
CXCR2 expression is related to of the metastatic potential in renal carcinomas
[165], adult myeloblastic leukemias [214], liver [215] and lung cancers [159]. The
most extensive evidence for CXCR2 expression/transformation/metastasis
comes from melanomas. CXCR2 is found on highly malignant melanoma cell
lines as well as from isolates of human melanomas [161, 216-218].
In GPCRs that have been mutagenized in vitro to generate CAMs, most
mutations mapped to the transmembrane regions, C-terminal region, and second
and third intracellular loops [81, 219]. However, no mutations or deletions in the
N-terminal domain have been identified that result in a constitutively active
chemokine receptor.
In this study, human CXCR2 is expressed a genetically engineered yeast
strain of Saccharomyces cerevisiae to screen for potential CXCR2 CAMs.
Randomly mutagenized copies of the CXCR2 ORF cloned into a yeast
expression plasmid allows for an unbiased selection of CAM receptors. From this
yeast screen we described a single amino acid substitution in the N-terminal
region of CXCR2 leads to a constitutively active CXCR2. Substitution of the
aspartic acid residue (D9) to amino acids with different properties results in
constitutive activity in yeast. These CAM receptors expressed in NIH3T3 cells
induce cellular transformation as evaluated by foci formation, anchorageindependent growth in soft agar and tumorigenesis in nude mice. In addition,
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these constitutively active receptors lead to a PLC β3 mediated signal
transduction cascade potentially induced by Gαq/11 as well as NF-κB activation,
which plays an important role in transactivation of angiogenic CXC chemokines
[220].
Our results suggest that the N-terminal domain of the CXCR2 plays an
important role in the regulation of structural constraints that serve as regulators of
receptor activation. In addition, differential usage of Gα proteins, such as Gαi
and/or Gαq/11, induced with the different CAM CXCR2 addresses important
aspects of functional selectivity.
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CHAPTER 3. MATERIALS AND METHODS

Yeast strains and expression vector
Genetically modified Saccharomyces cerevisiae strains, CY1141 (MATα
far1Δ1442 FUS1p-HIS3 ste14::trp1::LYS ste3Δ1156 gpa1(41)-Gαi2 lys2 ura3
leu2 trp1 his3) [185] and CY12946 (MATα FUS1p-HIS3 GPA1Gαi2(5) can1
far1Δ1442 his3 leu2 sst2Δ2 ste14::trp1::LYS ste3Δ1156 tbt1-trp1 ura3) [186],
were a generous gifts from Dr. J. Broach (Princeton University). The plasmid
p426 (ATCC #87361) contains the wild type or mutated CXCR2 gene under the
control of a constitutively active promoter (GPD) and URA3 auxotrophic marker.
Yeast cells were transformed each plasmid construct by the lithium acetate
transformation method [221].

β-galactosidase assay
Plasmid pMD1325 (a gift from Dr. Dumont M.E., University of Rochester,
School of Medicine and Dentistry) contains a FUS1-lacZ gene that is induced by
receptor activation [188]. β-galactosidase assays was performed as previously
described [191]. Briefly, yeast transformed with either wild type CXCR2 or
mutants and pMD1325 were grown overnight in selective growth medium at 30°C
to 5×106 cells/ml, washed by centrifugation, and grown for one doubling based
on hemocytometer count at 30°C. Basal activity of β-galactosidase was
measured by using a yeast β-galactosidase assay kit (Pierce) according to the
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manufacturer's protocols, activation is measured in Miller units. Comparing βgalactosidase activity for the wild-type strain normalized the activity of each
mutant.

Random Mutagenesis
Random mutagenesis was performed by error-prone PCR [189]. Primers
upstream and downstream of the CXCR2 ORF were synthesized to include
unique restriction sites (HindIII and XbaI). These were used in a mutagenic PCR
reaction that had three modifications in order to increase the mutagenic potential
of the reaction. First, low fidelity Taq polymerase was used (Takara Biosystems).
Secondly, the ratio of nucleotides used was altered to increase mistakes in the
polymerase. dTTP/dCTP was adjusted to 0.8 mM (final conc.) while the other
nucleotides remained at 0.25 mM [190]. Finally, manganese chloride was added
to final concentration of 500nM.

Immunofluorescence Microscopy
2.0×105 NIH3T3 and stable transfectant cells grown on Lab-Tek II
Chamber Slide (Nalge Nunc) were fixed with 4% paraformaldehyde for 10 min at
room temperature, permeabilized with Triton X-100 (0.01% in PBS) for 5 min,
and blocked with goat serum (1% BSA and 10% goat serum in PBS). Cells were
washed three times with 1ml of PBS. After incubated with mouse monoclonal
Na+/K+-ATPase (1:100, Santa Cruz Biotech) as a marker for plasma membrane
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localization for 2 h, cells were washed three times and incubated with rabbit
polyclonal anti-CXCR2 antibody (1:500, Abcam) at 4°C overnight. After washing
three times, cells were stained with Alexa Flour 488-conjugated goat anti-rabbit
IgG (1:500, Molecular Probes) and Alexa Flour 633-conjugated goat anti-mouse
IgG (1:200, Molecular Probes) for 30 min. After washing three times, cells were
mounted by SuperMount medium (BioGenex) and sealed with cover slip. The cell
was photographed with confocal laser scanning microscope (SP2 LSCM, Leica
Microincorporation Inc.) and analyze with ImageJ version 1.43 (Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/, 1997-2009).

Reagents
Selective CXCR2 inhibitor (SB225002, Cat.No. 559405), JAK inhibitor
(AG490, Cat.No. 658411), and Gαi inhibitor (Pertussis Toxin, Cat.No. 516562)
were purchased from Calbiochem. Phospholipase C inhibitor (U73122, Cat.No.
U6756) was purchased from Sigma-Aldrich.

Plasmids, Cell lines and Transfection
cDNA encoding human CXCR2 was provided by Dr. Philip M. Murphy
(National Institutes of Health). The luciferase reporter plasmid 3X MHC-Luc was
provided by Dr. Albert S Baldwin, Jr. (University of North Carolina School of
Medicine, Chapel Hill), and pRL-CMV (promega) was a gift from Dr. William E.

	
  

87	
  

Miller (University of Cincinnati College of Medicine, Cincinnati). Mouse fibroblasts
(NIH3T3) and human embryonic kidney cells (HEK293) were cultured in DMEM
(Dulbecco’s modified Eagle’s medium) containing 10% Fetal Clone (FC) 3.
Immortalized mouse melanocyte cell line, parental melan-a (a gift from Dr. Ann
W. Richmond, Vanderbilt University School of Medicine) was cultured as
previously described [222]. LipofectaminTM 2000 (Invitrogen) was used for both
transient and stable transfections. Stable cell lines (NIH3T3 or parental melan-a)
were selected with 800 µg/ml of G418 (Mediatech Inc.).

Site-Directed Mutagenesis
Single point mutations of CXCR2 in pcDNA3 were induced using the
QuikChange site-directed mutagenesis kit (Stratagene) according to the
manufacturer’s protocols. Mutations were confirmed by sequencing.

Single Nucleotide Polymorphism Genotyping
PCR for genotyping was done as followed by Masi et al [223]. The CXCR2
coding region from either genomic DNA of lung cancer cell lines were amplified
with

the

following

primers:

CXCR2

Forward

with

HindIII:

5’-

CCCAAGCTTATGGAAGATTTTAACATGGAGAGTG-3’ and CXCR2 Reverse
with XbaI: 5’-GCTCTAGATTAGAGAGTAGTGGAAGTGTGC-3’.
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Cellular transformation assays
The cellular transformation assay was performed as previously described
[93]. For foci formation assay, 100 stably transfected NIH3T3 cells were seeded
on top of 2.0×105 untransfected NIH3T3 cells in normal growth medium with 1 µM
of CXCR2 inhibitor (SB 225002, Calbiochem). Foci were photographed and
counted after 2 weeks. For the anchorage-independent growth assay, a total of
1.0×104 stably transfected NIH3T3 cells were cultured in 0.3 % agar containing
regular medium with SB 225002, on top of 0.6 % agar. Cells were fed every 3
days with 5 drops of growth media, and photographed after 3 wk. Photographed
images were analyzed using ImageJ version 1.43 (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/,
1997-2009).

Luciferase assays
NF-κB reporter assay was performed based on Sherril et al. [198]. To
measure basal level of NF-κB, HEK293 cells (4.0×105) were transiently cotransfected in a 6-well plate with 2.0 µg of 3X MHC-Luc, 0.5 µg of pRL-CMV as
an internal control, and 0.5 µg of CXCR2 constructs with LipofectamineTM 2000
(Invitrogen). At 24 hours post-transfection, transfected cells were synchronized
during 24 hours, and then assayed with Dual-GloTM Luciferase Assay System
following manufacturer’s protocol (Promega).
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Immunostaining for CXCR2 and phosphorylated signaling
molecules
For the staining of stable CXCR2 transfectants, PE-conjugated CXCR2
specific antibody (R&D Systems, Cat.No. FAB331P) was utilized. Analysis of
phosphorylated signaling molecules was performed as previously described
[224]. Briefly, stably transfected NIH3T3 cells were serum starved during 24 hrs
and fixed with 70% ethanol at -20°C for at least 1 hr, and then permeablized with
0.25% Triton X-100 in PBS on ice for 15 min. Permeablized cells were blocked
with 1% goat serum at room temperature for 30 min, and then cells were stained
with antibody specific phosphorylated PLC β3 (Santacruz Biotech. Cat.No. sc34392) and PKC α/β2 (Cell Signaling, Cat.No. 9375). Alexa Fluor® 488
(Invitrogen) was used as a secondary antibody.

Tumor Formation in vivo
Stably expressed NIH3T3 (2×105/mice) were injected subcutaneously into
the flanks of 6 to 8 wk old athymic nu/nu mice (Jackson Laboratory). The protocol
for animal experiment was reviewed and approved by the Institutional Animal
Care and Concerns Committee of the University of Tennessee.
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CHAPTER 4. RESULTS

Screening for CXCR2 CAMs using a genetically modified
Saccharomyces cerevisiae high-throughput system
Genetically modified yeast strains, CY1141 and CY12946, were used to
identify CXCR2 CAMs. CY1141 expresses a hybrid G alpha subunit, which
encodes the first 33 N-terminal residues of human Gαi2 replaced with the first 41
N-terminal residues of the endogenous yeast GPA1 protein. CY12946 contains a
modified Gα subunit with the last 5 C-terminal residues of yeast GPA1 replaced
with human Gαi2. These genetically modified G proteins allow coupling to the
mammalian receptor, which induces the yeast pheromone responsive signaling
pathway (Figure 12). To identify CXCR2 CAMs, wild type CXCR2 (WT_CXCR2)
was randomly mutated using error prone PCR and cloned into the yeast
expression vector, p426GPD. This plasmid contains an origin of replication, a
glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter driving expression
of the inserted open reading frame, and a uracil (URA) auxotrophic marker.
Transformation into the above mentioned yeast strains allowed for the selection
of CXCR2 CAMs that activated the signaling pathway, which leads to activation
of the pheromone responsive element and the gene for histidine auxotrophy. in
the presence of 3-AT.
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Figure 12. Schematic of yeast signaling used to identify CXCR2 CAMs.
Knock-out genes are showed in grey and an “X”. Expression of HIS3 is
under the control of the Fus1 promoter with a pheromone-response element
(PRE). The plasmid p426 contains the human CXCR2 gene under the control of
a constitutively active promoter (GPD) and URA3 auxotrophic marker. CXCR2
CAMs are selected on media lacking histidine and uracil in the presence of 3amino-1,2,4-triazole (3-AT) to suppress endogenous levels of histidine
biosynthesis.
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Approximately 300 yeast colonies grew on the His minus plates and 30
clones (approx. 30) were sequenced after retransforming the plasmids into
bacterium. Among them, a single point mutation in the N-terminus of CXCR2 was
identified as a CAM. The 9th residue (aspartic acid (D)) was mutated to a histidine
(H). The D9H mutant demonstrated constitutive activity (CA) in a β-galactosidase
assay in yeast (Figure 13). These factors led us to further investigate the role of
the 9th residue of CXCR2. To verify the cellular and structural function of the 9th
residue of CXCR2 in the N-terminus, different single point mutations were
generated in the 9th residue. Since WT_CXCR2 encodes the negatively charged
aspartic acid (D) at the 9th residue, we generated mutants encoding positively
charged amino acids, such as lysine (K), and arginine (R). An asparagine (N)
substituted CXCR2 was generated because we had identified this mutation from
a small cell lung cancer (SCLC) line, H69. As mentioned above (Part I in this
dissertation) mutation of the DRY motif in CXCR2 induces CA. Therefore CXCR2
DRY mutant, D143V, was also generated and used as a positive control in all
experiments.
After generating the CXCR2 mutants, the constitutive activity of each
receptor was measured. A β-galactosidase assay was used to measure the
degree of receptor activation in yeast using FUS1-lacZ reporter construct.

	
  

93	
  

Figure 13. Constitutive activity of CA CXCR2 measured via β-galactosidase
activity.
Yeast strain, CY1141, contains a plasmid, pMD1325, with the lacZ gene
under the control of the pheromone responsive element, FUS1. Yeast βgalactosidase assay kit (Pierce) was used to measure β-galactosidase activity
and is represented in Miller units. Bars represent the average of three
independent experiments plus/minus standard deviation. Student’s t-test
(PRISM(ver. 5.0b)

was used to determine statistical significance versus

WT_CXCR2 (*; p< 0.05).
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CXCR2_D143V shows the highest degree (approx. 20 folds over WT_CXCR2)
of receptor activation in the yeast. CXCR2_D9H and D9N mutants are also
higher than background (approx. 12 and 7 fold over WTCXCR2 respectively).
Also, the activity of CXCR2_D9K and _D9R demonstrate significantly higher
levels than WT_CXCR2 (p<0.05) albeit less than CXCR2_D9H and _D9N (Figure
13).

Establishment of NIH3T3 cell lines stably expressing CXCR2
CAMs
NIH3T3 cells, established from NIH Swiss mouse embryo culture, [225],
have been used historically for identifying transforming events. To identify fully
transformed cells due to CXCR2 CAMs, we generated clonal, stable NIH3T3 cell
lines. These lines were then used in various assays for assessing the degree of
transformation.
To verify the expression and localization, confocal microscopy was used
(Figure 14). As a positive control to verify plasma membrane localization, an
antibody specific Na+/K+ ATPase (Santa Cruz Biotech) was used. As shown in
figure 14, WT_CXCR2 and mutants co-localized with Na+/K+ ATPase indicating
WT_CXCR2 and CXCR2 CAMs are expressed on the plasma membrane. In
addition to localization, the expression level of each receptor was analyzed using
flowcytometry (Figure 15).
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Figure 114. Cell surface co-localization of CXCR2 CAMs with Na+/K+
ATPase in NIH3T3.
Stably transfected WT_CXCR2 and CXCR2 CAMs in NIH3T3 were fixed,
permeablized, and stained with a specific human CXCR2 antibody (Abcam,
Cat.No. ab14935) and Na+/K+ ATPase (Santa Cruz Biotech. Cat.No. sc-48345).
Alexa Flour 488 and 633 -conjugated secondary antibodies (Invitrogen) were
visualized and photographed at a magnification x100 by confocal laser scanning
microscope. Scale bar indicates 30.0 µm.
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The surface localization and relative expression level of the receptors for cell line
were verified with immunostaining followed by flow cytometery analysis (Calibur,
BD biosciences) (Figure 15). As shown in figure 15, all transfectants had similar
cell surface expression levels. Therefore, NIH3T3 cell lines stably expressing
WT_CXCR2 and CXCR2 CAMs had similar expression levels and were then
used in assays for assessing the degree of transformation.

CXCR2 CAMs induction of cellular transformation
Foci formation assays, which indicate the loss of contact inhibition
between adjacent cells, and growth in soft agar, which mimics anchorage
independent growth were used as measurements for the degree of cellular
transformation in our stable cell lines. Foci formation assay was performed by
seeding 100 stably transfected NIH3T3 cells on top of the untransfected NIH3T3
cells. NIH3T3 cells expressing CXCR2_D143V, which served as the positive
control, led to high numbers of foci as was previously report [93] (Figure 16).
Interestingly, cells expressing the CXCR2 CAMS (D9H, D9K and D9R) also
induced a high number of foci (average 50 number of foci). However cells
expressing WT_CXCR2 and CXCR2_D9N induced only a few foci. These data
show that CXCR2_D9H, D9K, and D9R are capable of transforming NIH3T3
cells while CXCR2_D9N does not.
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Figure 15. CXCR2 surface expression of stable transfectants.
Stable NIH3T3 transfectants were stained with PE conjugated CXCR2 specific
antibody and analyzed with flowcytometry (R&D Systems, Cat.No. FAB331P).

	
  

99	
  

Figure 16. CXCR2 CAMs differentially induce foci formation.
As a measure of their transformation ability, foci formation of stably transfected
WT_CXCR2 and mutants in the presence of CXCR2 antagonist (SB225002, 1
µM) were measured. Foci were photographed after 2 weeks, except D9K and
D9R mutants, which were photographed after 10 days. Bars represent the
average of three independent experiments +/- standard deviation. Student’s t-test
(PRISM (version 5.0b) was used to determined statistical significance verus
CXCR2_WT (*; p<0.05).
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Since

anchorage-independent

growth

strongly

correlates

with

tumorigenicity [226] and tumor metastasis [227], a soft-agar growth assay was
performed to assess anchorage-independent growth. Compared to WT_CXCR2,
_D9H,_D9R and_D9K showed significantly a higher number of colonies (Figure
17). In contrast, CXCR2_D9N was similar to WT_CXCR2. Interestingly,
CXCR2_D9K and D9R formed a higher number of colonies than CXCR2_D143V
(approx. 200 and 190 respectively), which is the positive control. Taken together
the oncogenic potential of CXCR2 CAMs, such as CXCR2_D143V, D9H, D9K
and D9R, was verified by their ability to form foci and colonies under soft agar
under the different conditions. Mutants D9K and D9R demonstrated the most
oncogenic activity because they had the most colonies and their foci developed
the fastest. Although CXCR2_D143V and D9H had a lower number of colonies in
soft-agar, these mutants showed a significant increase (*; p<0.05) compared to
WT_CXCR2 and D9N.

D9N was similar to background and does not have

transforming abilities.

CXCR2 CAMs induction of tumor formation in vivo
Since CXCR2 mutants induced cellular transformation in vitro, we
assessed the tumorigenic potential in vivo using hind flank injection of cells in
nude mice. Stable transfectants were injected subcutaneously into the flanks of 6
to 8 wk old athymic nu/nu mice (Jackson Laboratory). After inoculation, mice
were monitored and terminated once tumors reached 1.5 cm in any direction..
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Figure 17. CXCR2s CAMs lead to differential anchorage independent
growth.
Anchorage independent growth (i.e. growth in soft agar) was used as a measure
of cellular transformation. Each field is representative of the overall colony
formation in a six well dish (63x). Number of colonies were counted and
measured using ImageJ. Bars represent the average of three independent
experiments +/- standard deviation. Student’s t-test (PRISM (version 5.0b) was
used to determine statistical significance versus WT_CXCR2 (*; p< 0.05).
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As shown in Table 5, untransfected NIH3T3 cells injected into the flank of nude
mice did not show any tumor formation, but other mutants, including
WT_CXCR2,

showed

tumor

formation

at

the

injection

site.

However

CXCR2_D9K, D143V and D9H showed aggressive and fast tumor progression
compared to WT_CXCR2, which required a longer incubation period to form
tumors. Only 50% of the mice inoculated with cells expressing CXCR2_D9N
developed tumors and showed slow formation and were terminated at 73 days
after inoculation. These data indicate that constitutive activity induced by single
point mutation in the N-terminus of CXCR2 plays an important role in tumor
formation in vivo.

CXCR2 CAMs Induce differential signal transduction pathways
during foci formation
Based on phenotypic transformation in vitro and vivo, these data strongly
suggest that CXCR2 CAMs are oncogenic. These CXCR2 CAMs appear to
induce differential signaling pathways based on the degree of foci formation, soft
agar growth, and growth in vivo. In order to investigate the signal transduction
pathways that contribute to cellular transformation, a number of specific signal
transduction inhibitors were utilized. U73122 specifically inhibits PLC-β, which
prevents IP3 accumulation [228, 229].

	
  

103	
  

Table 5. Differential tumor growth in mice.
Number of mice with

Time until termination

tumors

(Days)

NIH3T3

0/10

.

WT_CXCR2

9/10

39

CXCR2_D143V

10/10

21

CXCR2_D9H

8/10

21

CXCR2_D9K

10/10

17

CXCR2_D9N

5/10

73

Transfectants

2×105 of NIH3T3 transfectants were injected into the flanks of 6 to 8 wk
old athymic nu/nu mice. Total mouse inoculated one cell line were termination
once the tumor develops approx. 1.5 cm from one mouse in each group.
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The PLC β pathway is downstream of Gαq/11 activation [67, 229]. AG490 was
used as an inhibitor of Janus Kinases (JAKs) which activate the transcription
factors (STATs) [230]. As mentioned above PTX prevents Gαi mediated signal
transduction cascade. Using these inhibits we mapped the downstream signaling
pathways that are induced in our stable transfectants.
As shown in Figure 18, WT_CXCR2 showed transforming potential in the
presence of IL-8, but in the presence of PTX formation of foci was inhibited
(Figure 18-A, P<0.05 compared with unstimulated WT_CXCR2). Therefore,
WT_CXCR2 activation with IL-8 induces Gαi mediated signaling pathways. PTX
also prevent approximately 50% of foci formation in the case of CXCR2_D143V
and D9R. However, statistical analysis using student t-test indicated that
CXCR2_D143V (P<0.05) is different compared with WT_CXCR2. Otherwise
CXCR2_D9R showed no difference compared with WT_CXCR2 (P>0.05). This
indicates that G protein usage can be different between WT_CXCR2 and
CXCR2_D143V. Previously Burger et al [93] also demonstrated that PTX only
partially (approx. 50%) prevents IP3 accumulation mediated by CXCR2_D143V
so our data match this previous publication. Surprisingly, CXCR2_D9H and D9K
show PTX independent foci formation implying that they not inducing the same
pathways as WT_CXCR2 or CXCR2_D143V.

CXCR2_D9R showed no

statistical difference with both WT_CXCR2 and CXCR2_D143V showing that this
is mutant is using a different pathway in spite of showing similar foci formation
with D9H and D9K. U73122 differentially inhibits foci formation mediated by
CXCR2 CAMs as well as WT_CXCR2 activation (Figure 18-B).
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Figure 118. Inhibitors define differential signal transduction pathways for
CXCR2 CAMs during foci formation.
Foci formation assay was performed in the presence of specific signal
transduction inhibitors: (A) PTX (100nM) for Gαi, (B) U73122 (2µM) for PLC-β,
and (D) AG490 (50µM) for JAK. Foci formation of WT_CXCR2 was induced with
IL-8 (100nM) stimulation as a positive control. Percentage reduction was
expressed as (the number of foci in the untreated samples- the number of foci in
the inhibitor treated samples / the number of foci in the untreated samples)x 100
**is this right? Statistical analysis using Student’s t-test (PRISM (version 5.0b)
was explained in the text.
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There is a statistically significant difference for CXCR2_D143V, D9H, and D9K
except

D9R

(p>0.05)

compared

with

WT_CXCR2.

Comparing

with

CXCR2_D143V and others indicated that CXCR2_D9H, D9K and D9R are not
statistically significant implying that they are using PLC β as part of their signaling
repertoire.
A number of CXCR2 CAMs, such as CXCR2_D9H, D9K and D9R,
showed a different combinational effect with both PTX and U73122 (Figure 18C). However, CXCR2_D143V only showed either PTX or U73122 dependent foci
formation not a combinational effect. Statistically CXCR2_D143V (p<0.05) and
D9H (p<0.05) showed a significant difference compared with WT_CXCR2. Only
CXCR2_D9H (p>0.05) presented is statistically significant compared with
CXCR2_D143V showing that this is using yet another more complex pattern of
signaling.
Interestingly, AG490 completely inhibited foci formation for WT_CXCR2
(Figure 18-D) and others indicating that the JAK-STAT signaling pathway is
directly involved in cellular transformation. This is a parallel result with a previous
study that showed AG490 completely prevented foci formation for WT_CXCR2
and CXCR2_D143V [114]. Taken together these data suggest that WT_CXCR2
and CXCR2 CAMs potentially activate Gαi and Gαq mediated signaling pathways.
In addition to Gα protein mediated signaling, the JAK-STAT signaling pathway
probably contributes to foci formation in a G protein independent manner.
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CXCR2 CAMs induction of constitutive PLC-β3 activation
Since CXCR2 CAMs demonstrated U73122 dependent foci formation,
activation of PLC β was tested to determine if the CXCR2 CAMs induce this
signaling pathway.

Phosphatidylinositol phospholipase C (PLC) plays an

important role in the induction of receptor mediated signal transduction through
the origination of the two kinds of secondary messengers that are inositol 1,4,5triphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5
biphosphate (PI2P) [231, 232]. There are a number of PLC isoforms that have
been described, such as PLC β1, PLC β2, PLC β3, PLC β4, PLC γ1, PLC γ2,
PLC δ1 and PLC δ2 [233]. Among these isoforms, the Gαq/11 family and certain
Gβγ subunits activate PLC β1, PLC β2 and PLC β3, and PLC β3 is
phosphorylated on Ser537 in the basal state [234-236]. Also IP3 and DAG
accumulation leads to intracellular Ca2+ release, which causes phosphorylation of
the protein kinase C (PKC) family [237, 238]. Therefore, modulation of PLC β3
and PKC mediated by CXCR2 CAMs was investigated by FACs analysis with
phospho-specific PLC β3 (Ser537) and PKC (α/β2) antibodies. Figure 19A shows
dephosphorylation of PLC β3 for WT_CXCR2 stimulated by IL-8 (100 nM) after
the cells were synchronized (serum starved). As mentioned above PLC β3 is
phophorylated on Ser537 in the basal state in cells. Therefore interaction
between WT_CXCR2 and IL-8 possibly induce PLC β3 activation (p<0.05). In
addition to WT_CXCR2, CXCR2 CAMs induced differential PLC β3 activation.
Interestingly, CXCR2_D9K (p<0.05) and D9H (p<0.05) activated PLC β3 more
than WT_CXCR2 stimulated by IL-8.
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Figure 119. CXCR2_CAMs induce differential signal transduction pathways
through PLC β and PKC.
Stably transfected NIH 3T3 cells were serum starved, permeablized, and stained
with phospho-PLC β3 specific antibody (A and B) (Santacruz Biotech) and
phospho-PKC specific antibody (D) (Cell Signaling). Induction of wild type
CXCR2 was performed with IL-8 (100nM) after serum starvation. Stained cells
were analyzed by FACs analysis (BD FACSCalibur). Data is representative of
three independent experiments. Student’s t-test (PRISM (version 5.0b) was used
to determine statistical significance (*; p< 0.05) (C and E).
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However CXCR2_D9N still remained at a basal level of PLC β3 phosphorylation
(p>0.05, Figure 19B and C).
As mentioned above, PLC β3 activation induces PKC phosphorylation.
Figure 19D and E indicated CXCR2_D143V (p<0.05) and D9K (p<0.05) lead to
phosphorylation of PKC, which means PKC is a potential downstream signaling
pathway for both CXCR2 CAMs. Taken together CXCR2 CAMs potentially utilize
the Gαq/11 family and one of downstream target pathway is PKC.

CXCR2 CAMs Transactivation of Epidermal Growth Factor
Receptor (EGFR)
The epidermal growth factor receptor (EGFR) activates several signaling
cascades in response to epidermal growth factor stimulation. One of these
signaling events involves JAK activation [239]. Since CXCR2 CAMs use JAK
dependent foci formation, the potential transactivation of EGFR was investigated.
To identify the IL-8 or CXCR2 CAMs mediated transactivation pathway,
the phosphorylation state of the EGFR was assessed in stably transfected
NIH3T3

cells

using

a

phospho-EGFR

specific

antibody

(pY1173,

BD

Biosciences). Figure 20 shows that CXCR2 CAMs differentially phosphorylate
EGFR. There is a also the possibility of autocrine EGFR phosphorylation
mediated by secreted EGF. To test this possibility, a mouse specific ELISA
assay was used to measure the concentration of mouse EGF. The concentration
of EGF was below the detection limit of 3 pg/ml indicating EGF independent
EGFR transactivation.
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Figure 20. CXCR2 CAMs induce EGF independent EGFR phosphorylation.
(A) Stable transfectants were serum starved, permeablized, and stained with
phospho-EGFR specific antibody (pY1173, BD Biosciences). Stained cells were
analyzed by FACs analysis (BD FACSCalibur). Data is representative of three
independent experiments. (B) Student’s t-test (PRISM (version 5.0b) was used to
determine statistical significance (*; p< 0.05).
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EGFR transactivation mediated by heterotrimeric G protein, Gαi
CXCR2

activation

mediated

by

IL-8

stimulation

led

to

EGFR

transactivation through heparin binding EGF (HB-EGF) [240]. Also, IL-8
stimulation of cathepsin B expression involved HB-EGF activation [240]. Since
the EGF concentration was undetectable, it is possible that there is a
transactivator that signals from the CXCR2 CAMs to EGFR. To investigate the
possible connection between CXCR2 CAMs and EGFR phosphorylation, the
CXCR2_D9R, which highly transactivated EGFR, and CXCR2_D9K, a more
modest

transactivator

of

EGFR

were

treated

with

PTX

and

EGFR

phosphorylation assessed. In Figure 21, PTX inhibited CXCR2_D9R/EGFR
transactivation suggesting that Gαi subunit is involved in EGFR transactivation.

CXCR2 CAMs Stimulation of NF-κB transcriptional activity
A number of studies have shown that GPCR CAMs stimulate NF-κB
transcriptional

	
  

activity,

which

induces
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cellular

transformation

in

vitro

Figure 21. CXCR2_D9R induce Gαi mediating EGFR transactivation.
NIH3T3 cell stably expressing WT_CXCR2, D9K and D9R were serum starved in
the presence of PTX (100ng/ml) for Gαi mediated signal transduction. Cells were
permeablized, and stained with phospho-EGFR specific antibody (pY1173, BD
Biosciences). Stained cells were analyzed by FACs analysis (BD FACSCalibur).
Data is representative of three independent experiments. (D) Student’s t-test
(PRISM (version 5.0b) was used to determine statistical significance (*; p< 0.05).
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Figure 22. CXCR2 CAMs induce differential basal levels of NF-κB
HEK 293 cells were co-transfected with luciferase reporter constructs for NF-κB.
For each transfection, luciferase activity was normalized for transfection
efficiency and measured with Dual-GloTM luciferase assay system (Promega).
Bars represent the average of three independent experiments +/-standard
deviation (* p≤ 0.05).
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and vivo [229, 241, 242]. In Figure 22, the basal level of NF-κB transcriptional
activity was assessed for WT_CXCR2 and CXCR2 CAMs using a luciferase
reporter assay. All CXCR2 CAMs induced NF-κB transcriptional activity except
mock control and WT_CXCR2. Although CXCR2_D9N did not induce any
phenotypic cellular transformation, the basal level of NF-κB transcriptional activity
indicated CXCR2_D9N induces constitutive NF-κB transcriptional activity. Thus,
there was no correlation between level of cellular transformation and NF-κB
activity.
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CHAPTER 5. DISCUSSION
The results from this study suggest that CXCR2 CAMs initiate the
activation of intracellular signal transduction cascades through multiple G
proteins usage, which are Gαi and Gαq/11 families (Figure 18). Surprisingly a
single point mutation in N-terminal 9th residue of CXCR2 caused this event.
Classically, CXC chemokine receptors were suggested to mediate
intracellular signaling through Gαi [93, 243]. Treatment of CXCR2 expressing
cells line with PTX completely disrupted IL-8 mediated inhibition of forskolinstimulated cyclic AMP accumulation, which indicates CXCR2 activation induces a
Gαi family dependent signal transduction pathway [153]. This Gαi dependent
signaling stimulates the accumulation of intracellular inositol phosphate and
increases intracellular calcium [150]. This induces a cascade of downstream
intracellular signaling pathways for cellular proliferation, migration, and inhibition
of apoptosis, and activation of NF-kB pathways [154-157]. Interestingly, our
results suggest a different view of Gα protein family usage for chemokine
receptors. WT_CXCR2 stimulated with IL-8 and CAMs probably induces a Gαq/11
mediating signaling as well as Gαi. CXCR2 activation mediated by IL-8
stimulation or CAMsexcept CXCR2_D9N, triggered differential PLC β3 and PKC
activation (Figure 19), and activates NF-κB transcription activation (Figure 22).
These G protein-dependent signal pathways, Gαq/11 – PLC β – PKC, and NF-κB
activation are also shown in virally encoded GPCR CAMs. Other virally encoded
CAMs such as human cytomegalovirus (HCMV)-encoded chemokine receptor,
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US28 [241, 244] and murine cytomegalovirus-encoded GPCR homologue, M33
[229] use Gαq/11 followed by PLC β and PKC activation [241, 245].
Interestingly, CXCR2_D9R potentially uses both Gαi and Gαq/11 proteins
cooperatively (Figure 18). Recently, promiscuous G protein usage was reported
by Kaposi’s sarcoma herpes virus (KSHV)-encoded GPCR, ORF74, which is a
homologue of human CXCR2 [197]. In primary effusion lymphoma (PEL)-derived
cell lines, KSHV ORF74 activates ERK and p38, and AP-1, NF-κB, CREB (cyclicAMP-response-element-binding protein) and NFAT (nuclear factor activator of T
cells) transcriptional factors concommitantly with Gαq/11 and Gαi. KSHV ORF74
utilized Gαi that induced AP-1 and CREB transcriptional activation via PI3K/AktSrc intracellular pathways. Gαq/11 usage of KSHV ORF74 led to transcriptional
activation of AP-1, CREB, and NFAT via ERK-1/2. However, NF-κB
transcriptional activation is probably mediated by not Gαi but Rac 1 [197].
Additionally US28 potentially uses promiscuous G-protein in a similar fashion
with KSHV ORF74 [102, 246]. US28 showed that Gαq/11 and Gβγ activate NF-κB
indicting a modulation of transcriptional factors through differential G protein
usage. Taken together, CXCR2_D9R seems to modulate multiple signal
transduction cascades through Gαq/11 and Gαi usage not like other CXCR2 CAMs
but like viral GPCR CAMs, which induces a potent of cellular transformation.
The mutation of the DRY motif from aspartic acid (D) to valine (V) at the
junction of third TM domain and intracellular loop was the first identified CXCR2
CAM [93]. The CXCR2 mutation in the DRY motif resulted in anchorage
independent growth and loss of contact inhibition. However, this result is quite
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reasonable due to the importance of D/ERY motif for G protein activation. In
addition to D/ERY motif, mutation or deletion of a non-TM region, such as a large
ectodomain [81, 97] and C-terminal intracellular domain [98], induces constitutive
activity. Our study is the first to describe an N-terminal single point mutation
causing chemokine receptor constitutive activity. One possible explanation is a
gain-of function phenotype induced by the loss of an intramolecular interaction
suggested by Kjelsberge et al [87]. In their study, mutation of Ala293 to one of
the 19 other amino acids in the α1B-adrenergic receptor resulted in constitutive
activation. Based on this report, they established propose a structural constraint
that maintains the receptor in the inactive state. Another possible explanation of
an N-terminal point mutation inducing CAM is the gain of intramolecular
interaction that induces differential activation. To confirm the mechanism for
constitutive activation mediated by N-terminal point mutations, additional
biochemical and biophysical studies will be necessary.
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CHAPTER 6. SUMMARY AND CONCLUSIONS

Much evidence suggests that CXCR2 activation is involved various types
of cancer development and metastasis. To elucidate CXCR2 activation and its
relationship with tumorigenesis, CXCR2 constitutively active mutants were
screened using a genetically modified Saccharomyces cerevisiae highthroughput system. Surprisingly, a single point mutation in N-terminal 9th residue
of CXCR2 led to constitutive activity, which motivated generating positive
charged substitutions, D9K and D9R, and D143V as a positive control for a
known CXCR2 CAM. Stably transfected NIH3T3 cells expressing CXCR2 CAMs
demonstrate the loss of contact inhibition and anchorage independent growth,
which are two characteristics of cell that have undergone cellular transformation.
Since the PLC β inhibitor U73122 and the Gαi inhibitor PTX were able to prevent
cellular transformation, PLC β and Gαi mediated signal transduction pathways
were investigated further. Interestingly, both IL-8 stimulation of WTCXCR2 and
the CXCR2 CAMs induced constitutive PLC β activation indicating that the Gαq/11
subunit family are involved. Additionally, CXCR2 CAMs induced differential basal
levels of NF-κB. Although CXCR2_D9N showed weak ability for cellular
transformation, NF-κB transcriptional activity showed higher levels than D9K and
D9R suggesting a high degree of cellular transformation. Using the inhibitor
AG490, the JAK pathway was shown to be directly involved cellular contact
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inhibition. Also, CXCR2 CAMs were demonstrated to transactivate EGFR in a
PTX sensitive fashion suggesting Gαi associated transactivation of EGFR.
Taken

together,

CXCR2

CAMs

mediate

constitutively

activated

intracellular signaling pathways, which are proposed in Figure 23. Our model,
based on our data, shows a complex relationship between CXCR2 activation,
downstream signaling and phenotypic readouts.

Treatment of cells with the

inhibitor for PLC β, U73122, showed that IL-8 stimulated WT_CXCR2 and
CXCR2 CAMs, such as D143V, D9H, D9K and D9R, induce Gαq/11 stimulation of
the PLC β pathway. All CAMs including CXCR2_D9N activate NF-κB
transcription. In the case of CXCR2_D9N, heterotrimeric G protein usage was
not investigated due to weak growth and low numbers of foci. However, low
activity in loss of contact inhibition and anchorage independent growth assays
potentially indicate that NF-κB activation may be involved in cell survival.
Because foci are still induced after using both U73122 and PTX inhibitors it is
possible that D143V and D9H possibly utilize another Gα family or the Gβγ
proteins, which are also capable of mediating downstream signal transduction
pathways. Interestingly, a specific inhibitor of JAK signaling, AG490, inhibited all
foci formation in all mutants tested. This strongly suggests that JAK-mediated
signaling is a pathway involved in cellular transformation. In order to investigate
where this signaling is initiated, we treated CXCR2_D9R with the EGFR specific
inhibitor, butain. In this case all foci formation was abolished. This demonstrated
that this specific EGFR-mediated signal transduction pathway is involved in
cellular transformation. This provides yet another pathway that contributes to foci
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formation.

In summary, our data shows that CXCR2 can use multiple Gα

proteins and that the CXCR2 CAMs can capture the differential activation states
and signaling pathways. Lastly, activation of CXCR2 leads to activation of the
EGFR receptor though an internal transactivation cascade. This internal
activation differentially transactivates EGFR in a PTX sensitive manner implying
the Gαi protein is the mediator of this activation. Additionally, a number of studies
suggest that EGFR activation potentially induces either JAK-independent or JAKdependent signalling through STAT1 or 3.
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Figure 22. Model for CXCR2 CAM induction of ligand-independent signal
transduction cascades.
Based on our data, CXCR2 CAMs, such as D143V, D9H, D9K and D9R,
including WT_CXCR2 stimulated with IL-8, possibly utilize Gαq/11 followed by
activation of PLC β. Interestingly, WT_CXCR2 stimulated with IL-8, D9R and
D143V potentially use both Gαi and Gαq/11. Combinational treatment with U73122
and PTX suggests D143V and D9H potentially induced constitutive signalling
through another Gα famiy or Gβγ protein. Moreover it has been shown that PLC
β can possibly be activated by Gβγ (blue dash line) [236]. Also all CXCR2 CAMs
induced JAK-mediated signaling. D9R induced transactivatation of EGFR
through Gαi. In addition it has been suggested that EGFR activation potentially
induces either JAK-independent or JAK-dependent signalling through STAT1 or
3 (orange dash line) [239, 247, 248].
Morphological cellular transformation was validated by loss of contact
inhibition and anchorage-independent proliferation assays. All of the CXCR2
CAMs

except

CXCR2_D9N

showed

both

characteristics.

demonstrated only anchorage-independent growth.
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CXCR2_D9N
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Constitutive Activity of Other CXCR2 Mutants in the Yeast

Introduction
As shown in part 4, genetically modified yeast encoding a part of
mammalian Gα protein sequence was used to screen a CAMs and the b
glactosidase activity was used to measure the degree of constitutive activity. This
appendix presents data for other CXCR2 mutants that we generated including
single point mutations, such as D9E, D9A, D9S and D9Y. Deletion mutants that
delete only the single D9 residue (ΔD9) and truncation mutants, such as Tru D9
truncate up to the 8th residue (serine), Tru S10 truncated through the 9th residue
(aspartic acid) and Tru C39 truncated to 38th residue (proline), which leaves the
cysteine residue intact.

Materials and methods
The experimental procedures are same as described in part 4 of chapter 3.	
  

Results
All mutants show very similar activity when compared with WTCXCR2
(Figure 24) except for D9A and D9Y albeit these mutants were much lower than
the positive control, D143V. These data show that not all mutations/truncations
within CXCR2 lead to constitutive activity in yeast. The next question that we
wanted to address is whether the lack of constitutive activity in these mutants is
also found in mammalian cells.
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Figure 23. Constitutive activity of CXCR2 mutants measured via βgalactosidase activity in yeast.
Yeast strain, CY1141, contains the plasmid, pMD1325, which has the
lacZ under the control of the pheromone responsive promoter. β-galactosidase
activity was measure using the yeast β-galactosidase assay kit (Pierce) and
represented in Miller units. Bars represent the average of three independent
experiments plus/minus their standard deviation. Student’s t-test (PRISM(ver.
5.0b) was used to determine statistical significance (*; p≤ 0.05).
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CXCR2 Mutants mediated Cellular Transformation

Introduction
As shown in Chapter 4, CXCR2 CAMs differentially induced foci formation
and anchorage-independent growth. This appendix presents the data about foci
formation and soft-agar growth assays for other CXCR2 mutants. In addition to
the mutations described early in this appendix, proline mutants, P266L and
P266L/Y267L, were generated based on evidence from Konopka et al that
showed mutations of residues Pro-258 and the adjacent Ser-259 to Leu leads to
constitutive activity [1].

Materials and Methods
The experimental procedures are the same as in part 4 of
chapter 3.

Results
Foci formation and growth in soft agar were used as indicators of cellular
transformation (Figure 24). As shown in Figure 24-A, only proline mutant, P266L,
formed statistically significant (p<0.05) number of foci (approx. 55 foci) compared
with WT_CXCR2, which indicates that the proline residue in TM6 plays an
important role in maintaining CXCR2 in an inactive status. However, double
mutant, P266L/Y267L, was not significantly different from WT_CXCR2. This

	
  

143	
  

differs with previous data from Ste2p_P258L/S256L, which increased CA over 90%
based on a β-galatosidase assay [1]. This could be due to the differences in
these receptors, the different readouts (β-galatosidase assay vs foci formation) or
the different cell types (yeast vs mammalian).
The soft-agar growth assay (Figure 24-B) demonstrated that deletion
mutant, ΔD9, was much greater than background

(p<0.05) number of colony

(20 colonies) albeit much lower than our previously described CXCR2 CAM. All
other mutants were not greater than WT_CXCR2 indicating they do not lead to
constitutive activity.
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Figure 24. CXCR2s CAMs lead to differential foci formation and anchorage
independent growth.
As a measure of their ability to transform cells, foci formation (A) and
anchorage-independent growth (B) of stably transfected NIH3T3 cells expressing
WT_CXCR2 or CXCR2 mutants in the presence of CXCR2 antagonist
(SB225002, 1 µM) were measured. Bars represent the average of three
independent experiments +/- standard deviation. Student’s t-test (PRISM (version
5.0b) was used to determined statistical significance versus CXCR2_WT (*;
p<0.05).
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CXCR2 Mutants and Ligand Binding

Introduction
To address whether the mutations in CXCR2 eliminated ligand binding, a
competition binding assay was performed to measure relative binding affinity.

Materials and Methods
Transiently transfected Cos-7 cells were seeded in a 48-well plate. At 48
hours post transfection, binding was performed on whole cells for 3 to 4 h at 4 oC
with125I-IL-8 in a binding buffer (50mM HEPES (pH7.4), 1mM CaCl2, 5mM
MgCl2, 0.5% bovine serum albumin). After incubation, cells were washed four
times with ice-cold binding buffer supplemented with 0.5M NaCl. Cells were
collected and counted in a Wallac Compugamma counter.

Result
All mutants except for the E198A and the double mutants used for other
experiments showed normal binding. This shows that the CXCR2 CAMs did not
alter binding to ligands and the alteration in conformation that leads to
constitutive activity does not affect the binding pocket. We have also carried out
our transformation assays in presence of ligands and saw no increase in foci or
colony formation (data not shown).
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IL-8 Binding Assay
[radioligand] = 0.2-0.4 nM
Receptor
WT
ΔD9
D9A
D9E
D9H
D9K
D9N
D9R
D9S
D9Y
E198A
D199A
E198A/D199A
D9K/E198A
D9K/D199A
D9K/E198A/D199A
D143V
R144A
II250-251ins

	
  

IC50 CXCL8
8.92 ± 0.05
9.01 ± 0.06
no binding
no binding
8.73 ± 0.09
8.56 ± 0.05
8.75 ± 0.18
8.69 ± 0.21
8.71 ± 0.06
8.81 ± 0.16
no binding
8.82 ± 0.20
no binding
no binding
no binding
no binding
9.28 ± 0.06
9.13 ± 0.11
8.65 ± 0.14
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n
8
4
2
4
7
2
3
3
3
4
4
4
4
1
1
1
4
4
3

CXCR2 CAM induction of Tumor Formation in vivo

Introduction
To address whether CXCR2_CAMs induce tumor formation in vivo,
transfectants were injected into the hind flanks of mice and the size of the tumor
was measured over time. Stable NIH3T3 transfectants were inoculated into nu/nu
mice (Jackson Laboratory) and Melan-a transfectants into C57BL6 mice
(Jackson Laboratory). The Melan-a cell line is a prototype of melanocytes and
was originally derived from C57/BL6 mice [2].

These transfectants were

generated to model melanoma development and allowed us to assess tumor
development in the context of an immune competent mouse.

Materials and Methods
CXCR2 stable transfectants or untransfected controls (2×105/mice) were
injected subcutaneously into the flanks of 6 to 8 wk old nu/nu mice (Jackson
Laboratory) and C57BL6 mice (Jackson Laboratory). Tumor size was measured
using a digital caliper. The protocol for animal experiment was reviewed and
approved by the Institutional Animal Care and Concerns Committee of the
University of Tennessee.

Results
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Our data shows that even WT_CXCR2 can form tumors in vivo. This
could be do to ligand engagement of the WT_CXCR2 receptor that contributes to
tumor growth. The in vivo administration of the CXCR2 inhibitor SB225002 did
not alter the growth of the tumors. There are multiple reasons for this. First,
there is no information about the bioavailability of this small molecule inhibitor.
Second, there is the possibility that once these cells have become transformed,
they no longer need ligand stimulation. There are several other possibilities for
this negative outcome. In the initial experiments using the Melan-A transfectants
only the D9N transfectant consistently formed tumors (Figure 29). In the repeat
experiment the D9N transfectants still showed significant tumor growth, but due
to tumor growth in some of the mice inoculated with untransfected controls, these
data are not significantly different (Figure 30).

Although these experiments

have led to confusing results, there is a definite trend towards D9N CXCR2
Melan-a transfectants leading to tumor growth.

If we are able to definitively

demonstrate this, it could mean that the D9N CXCR2 conformation stimulates
signaling pathways that contribute to tumor growth in this cell line while the other
CXCR2 CAMs do not. Only after further experimentation will we be able to make
this conclusion.
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Figure 25. Differential tumor formation in nu/nu mouse.
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Figure 26. Differential tumor formation in nu/nu mouse.
In a similar experiment, nu/nu mice were injected and some of the mice
were also injected with the CXCR2 inhibitor (I), SB225002, (1 mg/kg, i.p.) once
per a week.
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Figure 27. Effect of SB225002 for tumor formation in nu/nu mice
Note: WT CXCR2+I represents CXCR2 inhibitor, SB225002, injection into the
mouse (1 mg/kg, i.p.) once per week for the duration of the experiment.
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Figure 28. Differential tumor growth in nu/nu mice over time.
Weekly the size of the tumor (length x width) was measured. Bars represent the
average size of the tumors +/- standard deviation. Note: A “Dead Receptor”,
CXCR2_R144A, was used as an additional negative control. This receptor can
not respond to ligand.
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Number of mice
Days post
# of mice# with
of mice
tumors
with tumors
# Days
of mice
Post-inoculation
with
Daystumors
Post-inoculation
Days Post-inoculation
Transfectant
with tumors
inoculation
LLC
LLC
5/5
D9N
D9N
5/5
D9H
D9H
1/5
WTCXCR2
WTCXCR2 1/5
Untransfected
Untransfected
2/5

LLC 5/5
D9N5/5
D9H1/5
WTCXCR2
1/5
Untransfected
2/5

5/5
5/5
1/5
1/5
2/5

	
  

22
59
88
88
88

22
59
88
88
88	
  

22
59
88
88
88

Figure 29. D9N_CXCR2 transfectant leads to a more robust and early tumor
formation in BL6 mice.
After inoculation, whole groups of mice were removed from the study
when one mouse in group had a tumor size greater than 1.5 cm. At the time of
euthanization, the tumor size was measured.
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Figure 30. Differential tumor formation in C57/BL6 mice.
In a repeat experiment, tumor volume was measured. Bars represent the
average tumor volume +/- standard deviation.
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Establishment of Stable Cancer Cell Lines Overexpressing wild
type CXCR2 and CXCR2 Mutants

Introduction
As shown in part 4, mouse fibroblast cell line, NIH3T3, is a common cell
line used to address the cellular transformation potential of a protein. Both foci
formation and soft-agar growth assays show their relative transformed state.
However, in order to assess the real potential of CXCR2 CAMs in cancer
development, these proteins need to be analyzed in a real cancer environment.
Therefore, we established stable cell lines that express WT_CXCR2 and CXCR2
CAMs in human adenocarcinoma cells, A549, and androgen independent and
highly metastatic prostate cancer cell line, PC-3.

Materials and methods
The experimental procedures are same as described in part 4 of chapter
3.

Results
FACs analysis of stable cancer cell lines expressing WT_CXCR2 and
CXCR2 CAMS shows equal expression in both lines (Figure 25). Clones were
selected and used in our different assays.
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Figure 31. CXCR2 surface expression on stable transfectants.
Stable A549 and PC-3 transfectants were selected and stained with PE
conjugated CXCR2 specific antibody (R&D Systems, Cat.No. FAB331P).
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Differential Adhesion Molecule Expression in A549 stable lines

In order for cancers to metastasize, cancer cells may lose and/or gain
adhesive interactions in order to spread throughout the body. Adhesion
molecules, such as cadherins and cell adhesion molecules (CAMs), play an
important role the metastatic process [248]. The cadherins are membrane
glycoproteins that function in adherence in a calcium-dependent manner [249,
250]. One of the cadherins, E-cadherin, is expressed on epithelial cells and
maintains intracellular adhesion, so E-cadherin reversely correlates with cancer
cell metastasis [248]. Intercellular adhesion molecule-1 (ICAM-1) is the ligand for
LFA-1, an integrin found on leukocytes [251]. Activation of ICAM-1 induces
leukocyte binding to the endothelium through ICAM-1/LFA-1 interaction
eventually leading to transmigration into tissues [252]. MCAM is a melanoma cell
adhesion molecule and is used as a marker of the endothelial lineage [253].
MCAM is associated actin cytoskeletal rearrangements and plays a role in cellcell adhesion [254-256]. In order to address the role of CXCR2 stimulation in
cancer metastasis, our CXCR2 expressing A549 stable cell lines were stimulated
with the CXCR2 ligand, Gro-α, and the levels of different adhesion molecules
were measured.

Materials and Methods
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To observe the changes in adhesion molecule expression, A549 and A549
transfectants expressing either WT_CXCR2 or CXCR2_D9N were either serum
starved for 24 hours or starved and then stimulated with Gro-α (10nM) for the
final four hours. Harvested cells were stained with specific antibodies for ICAM,
MCAM, or N-cadherin (BD Biosciences). After staining, cells were washed, fixed
and analyzed using a FACs Calibur (BD Biosciences).

Results
A549 cell lines express CXCR1 but not CXCR2 but expression (Dr. Masi,
personal communication). Stable lines were stimulated with Gro-α as it only
stimulates CXCR2. The levels of adhesion molecule expression was measured
via flowcytometry as shown in Figure 26. ICAM is up regulated upon serum
starvation but down regulated upon Gro-α stimulation. In contrast, MCAM is only
upregulated in the CXCR2_D9N stimulated with Gro-α. E-Cadherin is
upregulated equally throughout. This demonstrates that over-expression and
stimulation of WT or D9N_CXCR2_ in adenocarcinomas can affect cellular
adhesion molecule expression that could relate to their metastatic ability.
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Figure 32. Alteration of adhesion molecule expression in CXCR2
expressing A549 stable lines upon exposure to Gro-α.
A549 lung cancer line transfectants were serum starved for 24 hours and
then stimulated with Gro-α (10nM) or mock for the final four hours. Cells were
then stained with the directly conjugated antibodies against the adhesion
molecules listed above.

Colored lines are Gro-α stimulated, black lines are

serum starved alone, and gray lines are unstained controls.
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